REVIEW

Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications

Minshan Guo, Xiaojie Sun, Jiahui Chen, Ting Cai*

State Key Laboratory of Natural Medicines, Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

Received 10 January 2021; received in revised form 22 February 2021; accepted 10 March 2021

KEY WORDS
Pharmaceutical cocrystals; Cocrystal engineering; Physicochemical properties; Solid dosage forms; Crystallization

Abstract  Pharmaceutical cocrystals are multicomponent systems in which at least one component is an active pharmaceutical ingredient and the others are pharmaceutically acceptable ingredients. Cocrystallization of a drug substance with a coformer is a promising and emerging approach to improve the performance of pharmaceuticals, such as solubility, dissolution profile, pharmacokinetics and stability. This review article presents a comprehensive overview of pharmaceutical cocrystals, including preparation methods, physicochemical properties, and applications. Furthermore, some examples of drug cocrystals are highlighted to illustrate the effect of crystal structures on the various aspects of active pharmaceutical ingredients, such as physical stability, chemical stability, mechanical properties, optical properties, bioavailability, sustained release and therapeutic effect. This review will provide guidance for more efficient design and manufacture of pharmaceutical cocrystals with desired physicochemical properties and applications.

© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

*Corresponding author.
E-mail address: tcai@cpu.edu.cn (Ting Cai).

Peer review under responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

https://doi.org/10.1016/j.apsb.2021.03.030
2211-3835 © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

The physicochemical properties, such as the stability, particle size, powder flowability, taste, hygroscopicity, solubility and compatibility, of active pharmaceutical ingredients (APIs) are critical attributes that impact the therapeutical effectiveness and manufacturing cost of solid dosage forms. In oral drug delivery systems, gastrointestinal absorption significantly depends on the solubility and dissolution rate of drug molecules. However, at present, approximately 90% of new chemical entities and 40% of currently marketed drugs belong to the Biopharmaceutical Classification System (BCS) II and IV classes, which suffer from the problems of poor water solubility and low bioavailability. As a result, the absorption of drugs in the gastrointestinal tract is limited, and subsequently, the clinical applications of drugs are hindered. Obviously, the physicochemical properties of pharmaceutical solids considerably influence the performance of drug products.

It is well known that the atomic packing in the unit cell and crystal lattice directly affects the properties of a given crystalline material. Therefore, modification of the physicochemical properties of solid drug forms can be achieved by tailoring the crystal packing arrangements. To date, several solid-state strategies have been applied to tune the properties of APIs, such as salts, polymorphs, hydrates, solvates and cocrystals (Fig. 1). However, these approaches have limitations; for example, only molecules with proper ionizable groups are suitable for salt formation, and hydrates/solvates are often not stable as water/solvent molecules are prone to lose over time. In comparison, any API (irrespective of acidic, basic or nonionized forms) has the opportunity to form cocrystals with a suitable coformer. Over the last two decades, pharmaceutical cocrystals have attracted significant attention from academia and pharmaceutical industries due to the potential to improve the physicochemical properties of APIs by modifying the crystal structure without altering the pharmacological nature. With the development of the cocrystal field, several pharmaceutical cocrystals have been approved, such as Steglatro®, Entresto®, and more are in clinical trials.

Pharmaceutical cocrystals are defined as crystals that comprise two or more discrete neutral molecules at a stoichiometric ratio and bond together via noncovalent bond interactions (e.g., hydrogen bonding, van der Waals and π–π stacking interactions), in which at least one of the components is API and the others are pharmaceutically acceptable ingredients. Since the early 2000s, it was realized that cocrystal engineering may be a potential approach to improve the physicochemical properties of pharmaceuticals, which was contributed to several representative pharmaceutical cocrystal publications in 2003–2004. These pioneering works emphasized the role of crystal engineering and supramolecular synthons in pharmaceutical-based cocrystal design, which encouraged the development of the cocrystal approach to improve the drug performance. Numerous robust supramolecular synthons have been identified and shown to play important roles in cocrystal design, constituting the driving force for pharmaceutical cocrystal formation. Several common functional groups are particularly amenable to the formation of supramolecular synthons of cocrystals, such as carboxylic acids, amides, and alcohols.

With the rapid development and increasing application of pharmaceutical cocrystals, the importance of pharmaceutical cocrystals has been concerned by regulators. In 2011, the U. S. Food and Drug Administration (FDA) first released a draft of guidance that categorized pharmaceutical cocrystals as drug product intermediates and defined them as “dissociable API-excipient molecular complexes wherein both API and excipients are present in the same crystal lattice.” However, researchers from industry and academia considered this definition too simple to clearly differentiate cocrystals. In 2016, the revised guidelines of the FDA described cocrystals as “crystalline materials composed of two or more different molecules within the same crystal lattice associated by nonionic and noncovalent bonds.” In 2018, the FDA described pharmaceutical cocrystals as “crystalline...
materials composed of two or more different molecules, one of which is the API, in a defined stoichiometric ratio within the same crystal lattice that are associated by nonionic and noncovalent bonds”. A coformer is “a component that interacts nonionically with the API in the crystal lattice, is not a solvent (including water), and is typically nonvolatile”27. The European Medicines Agency (EMA) defined cocrystal as “homogenous (single phase) crystalline structures made up of two or more components in a definite stoichiometric ratio where the arrangement in the crystal lattice is not based on ionic bonds (as with salts)”28. Compared to the definition of cocrystals by FDA, EMA described cocrystals as viable alternative to salts of the same API29. In other words, the cocrystal is considered the same as the API, except it shows distinct pharmacokinetic properties29. In this review, we will summarize the recent advances of pharmaceutical cocrystals, including preparation methods and modulations of physicochemical properties and applications of cocrystals. The solution-based method (including solvent evaporation, antisolvent method, cooling crystallization, reaction cocrystallization and slurry conversion) and the solid-based method (meat grinding, solid-based grinding and melting crystallization) will be introduced. Then, the different modulated properties and applications of cocrystals will be discussed, including physical and chemical stability, mechanical and optical properties, and in vitro and in vivo performance.

2. Cocrystal preparation

To date, widespread methods have been documented for cocrystal preparation, such as solid-state grinding, solution reaction crystallization, solvent evaporation, slurry conversion and melt extrusion. However, the selection of a suitable cocrystallization method remains empirical. Generally, the most widely used cocrystal formation approaches can be classified as solution-based methods and solid-based methods (Fig. 2). In solution-based methods, high solvent consumption is required for dissolving the cocrystal constituents. In addition, the choice of the solvent affects the results of cocrystallization, as it can change the intermolecular interactions between API and coformer. Conversely, solid-state methods offer the potential to eliminate the requirement of solvent use in cocrystal synthesis, where no or less solvent is required.

2.1. Solution-based methods

In these methods, there are ternary phases (API, coformer and solvent) in the solution, and the perfect state is that the cocrystal is supersaturated while the reactants (API and coformer) are saturated or undersaturated under the experimental conditions. Hence, the degree of supersaturation with respect to cocrystal in solution is the key parameter for cocrystallization and can be adjusted by the concentrations of API and coformer25. To guide the path of cocrystal formation, a phase diagram that describes the conditions for thermodynamic stability must be established, which can guarantee that the cocrystal stays in the thermodynamically stable region and exclude the crystallization of pure reactants. The location of thermodynamically stable cocrystal phase regions is mainly determined by the solubility of the reactants30. Fig. 3 demonstrates the ternary phase diagrams, which illustrate how to reach the supersaturation of cocrystals when the reactants are in a saturated or unsaturated state, according to the solubilities of reactants32. As shown in Fig. 3a, reactants A and B have similar solubilities and can be congruently saturated in the given solvent; thus, cocrystals can be formed in an equivalent reactant concentration. In Fig. 3b, the reactants exhibit different solubilities in noncongruently saturating solvents, in which the cocrystal can be generated by using nonequivalent reactant concentrations to reach the cocrystal stable region.

2.1.1. Solvent evaporation method

Solvent evaporation is the most common method for preparing cocrystals and is typically applied for synthesizing high-quality single-crystal cocrystals that suitable for structural analysis by single-crystal X-ray diffraction. In this approach, the cocrystal constituents completely dissolve in a suitable solvent at an appropriate stoichiometric ratio and then evaporate the solvent to obtain the cocrystal33. The selection of solvent influences the cocrystallization, which potentially impacts the solubility of the reactants. In a given solvent, the cocrystal components should be congruently soluble. If cocrystallization process occurs between two incongruently soluble components, the less soluble component precipitates preferentially, leading to a solid mixture of cocrystal and cocrystal components, or a failure of forming cocrystals. This technique has been employed to effectively synthesize many cocrystals33-35. For example, a block-shaped single crystal of a 1:1 febuxostat–piroxicam cocrystal, which interacted via a carboxylic acid–azole synthon, was formed by slow evaporation of acetone/MEK at room temperature for 3–5 days. The resulting cocrystal exhibited higher solubility and better tabletability than the corresponding components36. The cocrystals of nebivolol hydrochloride–nicotinamide with an improved dissolution rate were harvested by solvent evaporation37.

2.1.2. Antisolvent method

Antisolvent crystallization has been considered an effective approach to control the quality, particle size and properties of cocrystals, in which crystallization is conducted in semibatch or continuous manufacturing processes38-42. For instance, Chun et al.42 prepared the indomethacin–saccharin cocrystals via anti-solvent technique. As shown in Fig. 4, a solution of 0.034 mol/L indomethacin and 0.05 mol/L saccharin was mixed in 150 mL methanol, and 75 mL water (antisolvent) was then added to the solution vessel using a peristaltic pump with a 300 rpm stirring
solvent would bring more water molecules to coordinate with CBZ.

Since SAC exhibited a higher affinity for water than CBZ, the low content of SAC in the antisolvent cocrystallization of CBZ would retard the growth of the cocrystal and thus prevent the formation of CBZ hydrates. In a solution containing a coformer/drug ratio of 1:2; whereas CBZ hydrates would form below that ratio. In this study, the coformer concentration was fixed at 10%, and the initial drug concentration was increased from 10% to 50% using a 10% w/w solution of B. The volume ratio of methanol to water was pumped into the crystallizer for 10 s at 10 °C. To induce the nucleation of cocrystals, a 10% w/w seeding suspension was pumped into the crystallizer for 10 s at 10 °C.

2.1.3. Cooling crystallization

Cooling crystallization is a widely used method to prepare large-scale and purified crystals. In this method, the crystal properties of distribution size, purity, morphology and crystal polymorphism depend on the local supersaturation, which is determined by the process parameters, such as the transformation of mass and heat. Hence, these factors are required to be precisely controlled according to multiple solid–liquid equilibria in the cocrystal preparation process. In the crystallization process, the operating region depends on the stoichiometry of the cocrystal, as well as the thermodynamic stability zone of the cocrystal at the start and end temperatures. Several studies have shown that this method is an effective strategy for scale-up manufacturing of cocrystals. α-Lipoic acid–nicotinamide cocrystals with kilogram yields, 99% purity, and uniform particle sizes were obtained by a continuous oscillatory baffled crystallizer (Fig. 5) at a rate of 330 g/h. To induce the nucleation of cocrystals, a 10% w/w seeding suspension was pumped into the crystallizer for 10 s at 10 °C.

2.1.4. Reaction cocrystallization

Reaction cocrystallization is suitable for cocrystal formation when the cocrystal components possess different solubilities; the reactants with nonstoichiometric concentrations are mixed to generate cocrystal supersaturated solutions, leading to cocrystal precipitation. In this method, the nucleation and growth of cocrystals is controlled by the ability of reactants to decrease the solubility of cocrystals. The formation of meloxicam–salicylic cocrystals, carbamazepine–saccharin cocrystals and indomethacin–saccharin cocrystals has been achieved by reaction crystallization methods.

2.1.5. Slurry conversion

The slurry conversion method is a solution-mediated phase transformation process in which excess cocrystal components are required to be added to the solvent. During the slurry, each component gradually dissolves and forms a complex to promote the nucleation and growth of cocrystals. With the formation of cocrystals, the concentrations of the reactants are decreased, leading to undersaturation (with respect to the reactants) to continue to dissolve the cocrystal components. The operational range of the component’s concentration and temperature is controlled by the ternary phase diagram, which guides cocrystal supersaturation generation. Huang et al. found that the theophylline–benzoic acid cocrystal formation rate was significantly affected by the initial concentration of the components and the operating temperature, as evaluated by in-line Raman spectroscopy. The initial concentration of the reactants and the temperature showed a positive correlation with the cocrystal formation rate because a higher initial concentration could improve the collision probability of the components and total contact surface area; on the other hand, a higher temperature allowed the reactants to quickly reach the activated state.

2.2. Solid-based methods

Solid-state crystallization methods are effective and environmentally friendly in cocrystal formation as they need less or no solvent; the cocrystal forms spontaneously through direct contact or grinding with higher energy inputs. They are reasonable alternatives to solution-based cocrystallization methods, which might generate environmental hazards due to the large solvent.

---

Figure 3 Isothermal ternary phase diagram of a cocrystal: (a) similar solubilities of the API and coformer in solvent; (b) different solubilities of the API and coformer in solvent; 1: A and solvent; 2: A and cocrystal; 3: cocrystal; 4: mixture of B and cocrystal; 5: B and solvent and 6: solution. Adapted from the Ref. 32 with the permission. Copyright © 2008 Royal Society of Chemistry.

Figure 4 Experimental apparatus for the anti-solvent cocrystallization process. Adapted from the Ref. 42 with the permission. Copyright © 2013 Elsevier.
catalysts to accelerate the formation of caffeine–malonic acid cocrystals. Recently, it has been reported that cocrystals could be formed by exposing cocrystal components to suitable vapors\textsuperscript{65,66,69}. Optical microscopy studies on moisture-induced carbamazepine–nicotinamide cocrystal formation revealed that the deliquescence of components governed the cocrystal transformation, which led to localized dissolution of solid materials for crystallization\textsuperscript{70}. Huskic et al.\textsuperscript{71} discovered a complex and multistep dynamic pathway of cocrystal formation under methanol vapor using a benchtop powder X-ray diffractometer (Fig. 6). For carbamazepine–saccharine cocrystals, rapid formation of a short-lived crystalline phase was first observed, which then disappeared and transformed into monoclinic carbamazepine–saccharine cocrystal form II within 30 min\textsuperscript{71}. The transformation of the carbamazepine–saccharine cocrystal form II to triclinic form I occurred after 1 h. In addition, a 1:1 nicotinamide–suberic acid intermediate was detected first and then converted to a 2:1 nicotinamide–suberic acid cocrystal, indicating that formation was dictated by competition of supramolecular synthons\textsuperscript{71}. A similar observation was identified in the cocrystallization process of nicotinamide–fumaric acid cocrystal, in which the expected 2:1 nicotinamide–fumaric acid cocrystal was produced by a 1:1 nicotinamide–fumaric acid intermediate\textsuperscript{71}.

2.2.2. Solid-state grinding

The solid-state grinding method, which includes neat grinding and liquid-assisted grinding, is popular for producing cocrystals. The neat grinding method requires energy input to form the cocrystal by manual grinding (mortar and pestle) or mechanical milling (ball milling or vibratory mill) without the addition of a solvent. For liquid-assisted grinding, the cocrystal is formed by grinding with the assistance of a small amount of solvent.

2.2.3. Neat grinding

Previous studies have demonstrated that the potential mechanisms of cocrystal generation by neat grinding include molecular diffusion and the formation of a eutectic and or a transient amorphous intermediate\textsuperscript{22,73}. Grinding molecular diffusion is a process in which a mobile solid surface is created by grinding, which causes vaporization or energy transfer. Hence, high vapor pressure (10\textsuperscript{-3} to 10\textsuperscript{-4} mm Hg range) of the solid-state components (at least one of the components) is essential in the neat grinding process\textsuperscript{75}; thus, cocrystals could be formed on the crystal surface due to gas phase diffusion. Furthermore, grinding can offer energy for surface diffusion and migration to remove the generated cocrystal from the reactant surface to create a fresh surface for more cocrystallization\textsuperscript{74}. For example, Rastogi et al.\textsuperscript{74} found that the cocrystal formation of picric acid and aromatic hydrocarbons could be achieved by molecular diffusion with the aid of grinding. In the eutectic-induced cocrystallization process, (1) the continuous formation of an undercooled and metastable eutectic liquid phase on the fresh solid surface is indispensable and is created by agitation; (2) the nucleation of cocrystals from the eutectic phase could then be induced by grinding\textsuperscript{75}. Chadwick et al.\textsuperscript{74} observed a liquid eutectic phase on the interface of solids under a microscope during diphenylamine and benzophenone cocrystal formation. Furthermore, nucleation of cocrystals could lead to solidification of the liquid phase and result in the generation of cocrystals. For the amorphous-mediated cocrystallization mechanism, the strong intermolecular interactions between the API and coformer are the determining factors for cocrystal formation. A schematic diagram of a continuous oscillatory baffled crystallizer (COBC). Adapted from the Ref. 48 with the permission. Copyright © 2014 Royal Society of Chemistry.

Figure 5

2.2.1. Contact cocrystallization

It was found that the interactions between the API and coformer could spontaneously occur after “soft” mixing of the raw materials\textsuperscript{58–60}. The proposed possible mechanisms explaining spontaneous cocrystallization by contact are vapor diffusion of the two solids, moisture sorption, eutectic phase formation, amorphization and long-range anisotropic molecular migration\textsuperscript{61}. Higher humidity, higher temperature and smaller particle sizes of raw materials could facilitate cocrystal formation\textsuperscript{62}. MacFhionnghaile et al.\textsuperscript{63} described that caffeine–urea cocrystals were formed within 3 days by mixing separately premilling raw materials at room temperature and 30% relative humidity. The authors revealed that the interparticle surface contact between the solids was the key factor impacting the formation of caffeine–urea cocrystals. Ervasti et al.\textsuperscript{64} demonstrated that the phase transformation of theophylline–nicotinamide physical mixture to cocrystal was conducted without the assistance of any mechanical grinding. Another sample of spontaneous crystallization is the cocrystallization of isoniazid and benzoic acid, which illustrated that the rearrangement of cocrystals on the isoniazid surface was accelerated in the presence of moisture by promoting the interaction of isoniazid with benzoic acid vapor\textsuperscript{65}. Additionally, premilling of cocrystal physical mixture reduced the induction time of cocrystal nucleation and increased the cocrystal formation rate. Nartowski\textsuperscript{66} also revealed that the kinetics of spontaneous cocrystal formation were turned by tailoring moisture addition. The deliquescence of the malonic acid surface accelerated the transition rate of caffeine–malonic acid cocrystals\textsuperscript{66}. Ji et al.\textsuperscript{67} demonstrated that solvent vapors could act as
formation. Rodríguez-Hornedo et al. observed an amorphous phase during grinding of a mixture of carbamazepine and saccharine under the glass transition temperature, and cocrystal transformation occurred during storage at room temperature. In addition, the rate of cocrystallization of carbamazepine and saccharine was enhanced by the addition of water. Rehder et al. demonstrated that piroxicam–citric acid cocrystal formation is also an amorphous intermediate-induced cocrystallization process. For neat grinding, a stepwise mechanism of cocrystal formation has been proposed, in which the kinetic and thermodynamic cocrystal product was formed. This is a general feature if the reactant molecules have halogen- or hydrogen-bonding sites. This mechanism is most likely due to the hierarchy of strong and weak hydrogen bonding forces during cocrystal formation. The stepwise process of 2:1 nicotinamide–suberic acid cocrystal formation via neat grinding was observed by Karki et al. and Halasz et al., wherein the 1:1 nicotinamide–suberic acid cocrystal (NA–SUB) intermediate appeared first after grinding, followed by transformation to a 2:1 nicotinamide–suberic acid cocrystal (NA2–SUB). It was suggested that the formation of NA–SUB was kinetically driven by the strongest supramolecular synthons of amide–carboxylic acid \( R_2^2(8) \) and carboxylic acid–pyridine \( R_3^2(7) \) (Fig. 7). The thermodynamic product NA2–SUB was stabilized by many slightly weaker synthons of amide–amide synthons \( R_2^2(8) \) and \( R_3^2(7) \) pyridine–carboxylic acid.

### 2.2.4. Liquid-assisted grinding

The liquid-assisted grinding (LAG) method is useful for generating cocrystal products with high yields and high crystallinity compared to neat grinding. In addition, this method is suitable for rapid cocrystal screening, which is independent of the solubility of the raw materials. Enhanced molecular diffusion can be achieved by the addition of a small amount of liquid, which acts as a catalyst for accelerating cocrystal formation. The selection and amount of liquid play a key role in the mechanochemical reaction, influencing the formation of different solid products and the quality of crystals. Fischer et al. investigated the effect of solvent properties on 1:1 caffeine–anthranilic acid cocrystal polymorphs and found that the formation of form I appeared in the most of solvents. Form II was observed only in solvents with high dipole moments of carbonyl or nitrile groups. It was explained that the precoordination of solvent molecules with the amino group of anthranilic acid led to the torsion of the caffeine at the amino-carbonyl hydrogen bond; thus, form II with a zigzag packing structure was formed rather than form I with a planar layered structure (Fig. 8). The authors explained that the solvent molecules occupied many sites so that the interaction

---

**Figure 6** (A) The molecular structure of carbamazepine, nicotinamide, saccharine, fumaric and suberic acid. (B) Side-on and top views of the sample holder. Adapted from the Ref. 71 with the permission. Copyright © 2016 Royal Society of Chemistry.

**Figure 7** (A) Hydrogen-bonded chain of (NA–SUB) and (NA2–SUB). Adapted from the Ref. 78 with the permission. Copyright © 2013 John Wiley and Sons. (B) Structure of supramolecular chains of (NA–SUB) and (NA2–SUB). Adapted from the Ref. 77 with the permission. Copyright © 2009 Royal Society of Chemistry.
between caffeine molecules and the amino group of anthranilic acid could not take place in the same planar layer, causing caffeine twisting at approximately 30°.

Recently, Germann et al.80 reported a hitherto unexplored effect of milling assembly on reversible mechanochemical polymorphs between stable form (form I) and metastable phases (form II) of nicotinamide–adipic acid (NIC–ADI) cocrystals during LAG, challenging the Ostwald rule of stages (Fig. 9). Both polymorphs showed zigzag structures, wherein each ADI molecule participated in the formation of two $R_2^2(7)$ or $R_2^2(8)$ synthons in form I but every ADI molecule was involved in forming both $R_2^2(7)$ and $R_2^2(8)$ motifs in form II. The corresponding relative energies of form I and form II were $-7.5$ and $-10.2$ kJ/mol, respectively. In all experiments, during the grinding process by 7 mm stainless steel ball milling with acetonitrile, the intermediate 2:1 nicotinamide–adipic acid cocrystal (NIC$_2$–ADI) was initially obtained. Then, metastable form II was obtained in the stainless steel jar, while thermodynamically stable form I was formed in the poly(methyl methacrylate) (PMMA) jar. In addition, form II could convert to form I by grinding in a PMMA jar, which is consistent with the Ostwald rule of stages. The opposite process was observed in the stainless steel jars, indicating the transformation of stable form I to metastable form II, in contrast to the Ostwald rule of stages. The authors speculated that this surprising phenomenon was due to the more efficient transfer of mechanical energy in the stainless steel jar (higher elastic properties) than that in the PMMA jar. Additionally, the different materials of the milling ball also significantly influence the polymorphism80. In the PMMA jar with stainless steel balls, transformation of the metastable form to the stable form was observed80. However, the conversion of form I into form II occurred in the PMMA jar when elastic zirconia (ZrO$_2$) balls were used to mill the raw materials80.

Ionic liquid-assisted grinding is an emerging approach in mechanochemistry in which ionic liquids are used to replace organic solvents. In comparison with solvents, ionic liquids (ILs) have short- and long-range interactions between cations and anions, causing the properties of ILs to be controlled by modified individual or dual ionic components. The polymorphs of caffeine–citric acid cocrystal (CAF–CA) and caffeine–glutaric acid cocrystal (CAF–GLU) were successfully generated by using ionic liquids (imidazolium-based) as grinding liquids81. It was found that the hydrogen bonding ability of cations plays a key role in CAF–CA cocrystal form I formation rather than the polarity of the ionic liquids81. For the CAF–GLU cocrystal, hydrophobic and nonpolar ILs stabilized the nonpolar slip plane (200), resulting in the formation of form I81. The alkyl chain length of the imidazolium cation presented a negative correlation with the cocrystal formation rate. Furthermore, the change in the hydrophobic to hydrophilic properties of cations led to the alteration of form I to form II81.

2.2.5. Melting crystallization

Melting crystallization is an alternative green approach for preparing pharmaceutical cocrystals85. Although solvents are not involved in this approach, the thermal stability of drug and coformer should be carefully evaluated in advance82. Yan et al.82 synthesized melatonin–pimelic acid cocrystal by the melt crystallization. The melatonin–pimelic acid cocrystals were formed when the molten mixture was in the temperature range of 50–70°C. The carbamazepine–nicotinamide cocrystal was prepared by melting the physical mixture of drug and coformer at 160°C and then cooling the melt to the ambient temperature for crystal growth83. Rodriguez-Hornedo and coworkers have investigated the crystallization pathways of the carbamazepine–nicotinamide cocrystal from the melt upon heating84. Two different pathways were found at the different heating rates: (1) at the slow heating rate (3°C/min), a metastable phase of carbamazepine–nicotinamide cocrystal firstly nucleated and then transformed to the stable form; (2) at the fast heating rate (10°C/min), the individual components of cocrystal crystallized first, then they were melted and the stable form of the cocrystal grew from the melt83.

3. Physicochemical properties and applications of cocrystals

3.1. Physical stability

A physical change is a change in the state of a substance without any accompanying change in the chemical composition of the substance. The physical properties of solid-state materials include melting point, hygroscopicity, solubility, hardness, plasticity, elasticity, etc. Cocrystallization is a powerful approach for improving the physical properties and maintaining the physical stability of drug substances85,86, which may suffer undesired physical transformation during manufacturing and storage. Herein, we will discuss only the melting point and hygroscopicity in this section, and other properties will be discussed in the following sections.

3.1.1. Melting points

For manufacturers, solid drug forms provide a convenient way to purify, identify, transport, and store drugs. For patients, solid forms are more convenient to carry and administer than liquid forms87. However, some drugs exist in a liquid state at room temperature due to their low melting points. Cocrystallization has the potential to alter the melting point of liquid drugs by incorporating a suitable coformer into the crystalline lattices. Propofol
is applied to induce and maintain general anesthesia and sedation. It is formulated as an oil-in-water emulsion because of its low melting point (18 °C), resulting in associated problems including instability, pain on injection and hyperlipidemia. McKellar et al. adopted cocrystal approach to obtain a novel solid form of propofol using isonicotinamide as the coformer (Fig. 10). The propofol–isonicotinamide cocrystal is a stable solid at room temperature due to the increased melting point (~50 °C higher melting point than that of the starting material). Another study reported by Bacchi et al. showed that cocrystals of propofol–bipyridine and propofol–phenazine could convert liquid propofol into a crystalline phase.

3.1.2. Hygroscopicity
The hygroscopicity of a drug substance must be thoroughly investigated because it could impact the physicochemical properties, e.g., solubility, dissolution rate, stability, bioavailability and mechanical properties. For example, dasatinib anhydrate exhibited higher solubility than the monohydrate form. Therefore, maintaining the hygroscopic stability of the anhydrate form is one of the major challenges during drug development. Several strategies have been applied to tackle this challenge, including adding appropriate excipients in the formulation, applying proper packing for reducing moisture uptake or coating the drug product by enteric polymers. Indeed, some studies have demonstrated that cocrystal formation could improve the hygroscopic stability of drugs. Huang et al. demonstrated that flavonoid–theophylline cocrystals exhibited greater resistance to hydration than theophylline alone.

Caffeine is a natural alkaloid found in coffee and tea and easily forms a nonstoichiometric crystalline hydrate under humid conditions. Six cocrystals of caffeine with oxalic acid, malonic acid, maleic acid, and glutaric acid were prepared by Trask et al. Among the six cocrystals, the 2:1 caffeine–oxalic acid cocrystal exhibited superior hygroscopicity stability under humidity stress for several weeks. Zileuton (ZIL) was the first drug approved for the maintenance treatment of asthma by the FDA, showing a tendency to form a stable hydrate form under moisture conditions. Cocrystals of ZIL with nicotinamide and isonicotinamide were prepared by the slurry method and demonstrated to have better hygroscopicity stability at 40 °C/75% RH for 4 weeks compared with the drug substance alone.

Lithium chloride (LIC), used for neuropsychiatric disorders, is extremely hygroscopic and rapidly deliquesces even at 11.30% RH, which limits its development as a drug substance. The cocrystal of LIC with glucose (GLU) showed modestly improved hygroscopic stability under 40% RH and comparable in vivo pharmacokinetics to those of LIC. Another example of cocrystals stable to hydration is metoclopramide (MCP), a widely used antiemetic drug marketed as metoclopramide hydrochloride (MCP HCl) salt. In the monohydrate form, crystallized water could trigger an ion–exchange reaction with KBr and increase the rate of the Maillard reaction with lactose during the manufacturing process. The hydration of MCP HCl was effectively inhibited by using an oxalic acid cocrystal. All hydrogen bond donor and acceptor sites of MCP participated in the formation of the cocrystal, accounting for the improved stability against the moisture.

Figure 9: Schematic representation of the impact of the milling assembly, the choice and material of milling jar and balls, on the polymorphism in mechanochemical cocrystallization. Adapted from the Ref. with the permission. Copyright © 2020 Royal Society of Chemistry.
The nootropic drug oxiracetam (OX) is a racemic compound consisting of S-OX and R-OX. It has been reported that S-OX has a better therapeutic effect than R,S-OX in the treatment of cognitive dysfunction, while S-OX is more hygroscopic than R,S-OX. Hygroscopic tests showed that the S-OX–gallic acid cocrystal was less hygroscopic compared to the S-OX alone and the racemic parent drug, which could be attributed to the generation of complex and robust hydrogen bonded frameworks through cocrystallization.

### 3.2. Chemical stability

Chemical degradation of drug substances tends to occur during the manufacturing and storage stages, which challenges the development of a stable pharmaceutical formulation. It is critical to develop an effective strategy to eliminate or minimize drug degradants. Recently, pharmaceutical cocrystals have emerged as a prospective approach to overcome the chemical instability of APIs in the solid state. Table 1 shows the list of cocrystals with enhanced photostability. Hence, this section is focused on discussing the mechanisms by which cocrystallization solves the problem of chemical degradation through changing the crystal packing of APIs. The factors giving rise to the enhancement of solid-state chemical stability by pharmaceutical cocrystals were summarized in Fig. 11. In particular, structure–property relationships were established to further provide theoretical guidance for addressing the chemical stability issues of drug candidates.

The reaction cavity refers to the space near the reaction groups in the crystal structure. A large reaction cavity causes high molecular mobility and a high probability for the occurrence of solid-state chemical reactions. Epalrestat (EPR), which is used for molecular mobility and a high probability for the occurrence of solid-crystal structure. A large reaction cavity causes high mobility for addressing the chemical stability issues of drug candidates.

The distance between reactive sites plays a key role in the chemical stability of crystalline solids. For example, the drug–drug cocrystal of vitamin D3 and vitamin D2 with a greater distance between reactive sites in vitamin D resulted in improved chemical stability. Nicorandil (NCD) is an effective drug for cardiovascular disorders, suffering from low chemical stability under high humidity, heat and mechanical stress. In the crystal packing of NCD, the distance between lone pair electrons on pyridines (N1) and C8 of the nearby NCD molecule is 3.367 Å, which is shorter than the sum of the van der Waals radii of C and N (3.484 Å). The close contact between N1 and C8 could facilitate the degradation process by stabilizing the carbocations (C8⁺) of degradation intermediate Ia. Guo et al. developed a series of nicorandil cocrystals with 1-hydroxy-2-naphthoic acid (1-HNA), salicylic acid (SA), 3-hydroxybenzoic acid (3-HBA), and 2,5-dihydroxybenzoic acid (2,5-DHBA). All cocrystals exhibited superior hydrothermal stability in comparison with that of NCD alone. The crystal structure of cocrystals revealed that the distances of N1–C8 were elongated and longer than the sum of the van der Waals radii of C and N. Hence, the carbocations (C8⁺) in Ia cannot be stabilized by N1, resulting in inhibition of the catalyzed effect on the decomposition process of NCD.

![Figure 10](image.png) Conversion of liquid propofol to crystalline solid with the higher melting point by crystallizing with isonicotinamide. Adapted from the Ref. 87 with the permission. Copyright © 2014 American Chemical Society.

| API                  | Coformer                        | Ref. |
|---------------------|---------------------------------|------|
| Furosemide          | Caffeine                        | 115  |
| Brexiprazole        | Catechol                        | 108  |
| Nifedipine          | Isonicotinamide                 | 116  |
| Progesterone        | Phloroglucinol                  | 85   |
| Antiprotozoal tinidazole | p-Aminobenzoic acid             | 117  |
| Levofloxacin        | Metacetamol                     | 95   |
| Epalrestat          | Betaine                         | 104  |
| Linagliptin         | Ferulic acid                    | 118  |
| Vitamin K3          | 1-Hydroxy-2-naphthoic acid      | 114  |
|                     | 6-Hydroxy-2-naphthoic acid      | 114  |
| Tranilast           | Urea                            | 119  |
|                     | Nicotinamide                    | 119  |
| Nitrofurantoin      | 4-Hydroxybenzoic acid           | 120  |
| Vitamin D3          | Vitamin D2                      | 106  |
Brexpiprazole (BREX) has been widely applied for the treatment of atypical psychotic disorder\(^{107,108}\). It exhibits poor photostability in the presence of the polyvinyl pyrrolidone (PVP) polymer\(^{108}\). The nitrogen atom on the piperazine ring of BREX is prone to react with the peroxide in PVP and degrade into the N-oxide impurities. The brexpiprazole–catechol cocrystal (BRC cocrystal) completely prevented the transformation of brexpiprazole to N-oxide degradants at 40 °C/75% for one month\(^{108}\). The improved stability of the BRC cocrystal for brexpiprazole was attributed to the strong hydrogen bonds between the piperazine ring (3.013(3) Å, 2.320 Å, 142.09°), which formed between the piperazine ring of BREX and the catechol molecule. The strong intermolecular interactions blocked the reactive site of the nitrogen atom on the piperazine ring, and consequently, direct contact with the peroxides was prevented\(^{108}\).

Adefovir dipivoxil is an oral prodrug of adefovir with poor chemical stability\(^{109,110}\). Two degradation pathways, hydrolysis of the pivaloyloxymethyl moiety and dimerization of the adenine ring, were observed in the solid state\(^{111,112}\). Gao et al.\(^{112}\) demonstrated that coformer selection for cocrystal design plays a decisive role in maintaining the solid-state hydrolytic stability of adefovir dipivoxil. Cocrystals with weakly acidic saccharin and basic nicotinamide were successfully designed and investigated. The contents of the degradation product followed the order adefovir dipivoxil–saccharin cocrystal < adefovir dipivoxil < adefovir dipivoxil–nicotinamide cocrystal after chemical stability testing for 30 days. The reason that the specific adefovir dipivoxil–saccharin cocrystal exhibited enhanced chemical stability for adefovir dipivoxil was explained by the weakly acidic nature of saccharin; thus, the adefovir dipivoxil molecule was present in a weakly acidic microenvironment, and the hydrolysis degradation of adefovir dipivoxil was inhibited. However, the nicotinamide provided a basic environment for the adefovir dipivoxil molecule, accounting for the acceleration of hydrolysis degradation.

Menadione (MD) is known as vitamin K3 and can undergo [2 + 2] photodimerization degradation in the solid state (Fig. 14A). Under sunlight, MD molecules are reoriented to an appropriate geometry for photodimerization by forming two cyclobutane photodimers\(^{113,114}\). Zhu et al.\(^{115}\) prepared three MD cocrystals with 1-hydroxy-2-naphthoic acid (1-HNA), 6-hydroxy-2-naphthoic acid (6-HNA), sulfamerazine (SUL), and investigated the effect of cocrystals on the photodimerization. As expected, no obvious color change or degradation was observed for three cocrystals under 4500 lux illumination for 5 days, while a noticeable color change was observed in MD alone (Fig. 14B). It was proposed that the superior photostability of the cocrystals may result from the enhanced π⋯π stacking between MD and coformers; hence, the coformer acted as a blocker to prevent the MD molecule from approaching each other and photocyclizing\(^{114}\).

### 3.3. Mechanical properties

The mechanical properties of crystalline materials are critical attributes to various manufacturing processes of solid dosage forms, such as blending, milling, granulation, tableting, and coating. For solid materials, the mechanisms of mechanical deformation consist of elastic, plastic, viscoelastic, and fragmentation. Generally, materials with better plasticity properties could exhibit superior compressibility, which is permanent and irreversible after the removal of stress. However, many organic compounds have poor mechanical properties, which poses a hurdle for developing tablet formulations. Cocrystallization has been demonstrated to effectively improve the mechanical properties of drugs by altering crystal packing\(^{116–120}\).

Good tableting behavior anticipates more plastic deformation and less elastic recovery for organic materials. Crystal structures with slip planes would facilitate plastic deformation and eventually improve the bulk compaction behavior\(^{120,130}\). Singaraju et al.\(^{125}\) evaluated the compaction performance and mechanical properties of caffeine cocrystal polymorphs. The mechanical and energy framework data suggest that the better plastic deformation of caffeine–3-nitrobenzoic acid cocrystal form I (in comparison with form II) can be attributed to its 2D-layered crystal structure. For example, the powder Brillouin light scattering spectra of form I showed the presence of low-velocity shear modes, and energy framework calculations identified that a favorable slip system existed in form I\(^{125}\). Furthermore, Mishra et al.\(^{133}\) investigated the mechanical properties of caffeine–glutaric acid cocrystals on different crystalline faces by nanoindentation (Fig. 15). They found that the anisotropic mechanical responses of polymorphs depended on the number of possible slip planes and the strength of the intermolecular interactions in the crystal structure with respect to the direction of indentation. The presence of higher interlayer energy, strong intermolecular interactions, and a lack of facile slip planes in form II yield hard materials (Fig. 15B and C). More facile slip planes and weaker intermolecular interactions caused form I to be soft. The results of mechanical properties indicate that form I is a potential candidate with superior tabletability compared to form II. Another example elaborated the mechanical behaviors of chlorzoxazone (a first-line therapy for muscle spasms) was reported by Roy et al.\(^{122}\). Chlorzoxazone shows poor compressibility so that the wet granulation is applied to manufacture tablets. The tensile strength of tablets with chlorzoxazone alone was lower than 0.8 MPa at a compression pressure of 50 MPa. While the tensile strength of chlorzoxazone–picolinic acid cocrystals was approximately 1.6 MPa at 250 MPa without any capping or lamination. The denser packing of cocrystals (relative to pure chlorzoxazone) accounts for the enhanced bonding strength. In addition, the slip planes in the cocrystal...
structure give rise to better plastic deformation of the material, resulting in the improved compressibility\textsuperscript{132}.

The punch sticking is a common problem in manufacturing tablets, where powder materials adhere to the punch surface during tableting. Based on the Paul-Sun punch sticking model, F\textsubscript{1} (API-punch adhesion), F\textsubscript{2} (API-API cohesion) and F\textsubscript{3} (API-excipient adhesion) play a key role in the punch sticking propensity\textsuperscript{133}. There are three situations according to the values of F\textsubscript{1}, F\textsubscript{2} and F\textsubscript{3}: (1) if F\textsubscript{1} is higher than F\textsubscript{2} and F\textsubscript{3}, API sticking will occur; (2) if F\textsubscript{2} < F\textsubscript{3}, only a monolayer of API will form on the punch; and (3) if F\textsubscript{2} > F\textsubscript{3}, the layer coated on the punch tips will continuously build up\textsuperscript{134}. APIs with high plasticity exhibit serious punch sticking issues due to their increased contact area of API-punch and API-API and thereby enhance the values of F\textsubscript{1} and F\textsubscript{2}. Sun and coworkers\textsuperscript{134} speculated that this problem could be minimized or even eliminated by using a harder crystal form.

Celecoxib (CEL) is a nonsteroidal anti-inflammatory drug for the treatment of arthritis, acute pain, and menstrual pain. The CEL exhibits a serious punch sticking propensity due to the presence of slip planes in the crystal structure. The cocrystal of celecoxib–\textgamma-proline (CEL–PRO) shows a lower punch sticking propensity than the pure CEL due to the formation of strong interlayer bonding energy, deactivating slip planes and weaker API-API interactions (F\textsubscript{2}) in the structure of the cocrystal (Fig. 16B and C)\textsuperscript{134}. Furthermore, according to the results of the molecular electrostatic potential maps, the electronegativity of the exposed portion on the pyrrolidine group in \textgamma-proline is lower than that of the carbon–fluorine functional group of CEL, resulting in the exposure of electronegative groups on the punch tips decreasing and hence lowering the initiation of sticking (reduced F\textsubscript{1})\textsuperscript{134}. Therefore, celecoxib–\textgamma-proline cocrystals are more suitable for tableting than the pure CEL crystals.

Organic crystals are usually brittle and fragile, which largely limit their applications in the fields of pharmaceuticals\textsuperscript{135}, biomaterials\textsuperscript{136}, optoelectronics\textsuperscript{137}, fluorescence\textsuperscript{138} and semiconductors\textsuperscript{139}. Recently, some studies have reported that a few organic materials could achieve high flexibility by cocrystallization with a suitable coformer\textsuperscript{140,141}. Ghosh et al.\textsuperscript{140} reported a remarkably elastic and bendable cocrystal of caffeine–4-chloro-3-nitrobenzoic acid methanol solvate, which displayed reversible blending after withdrawing the mechanical force (Fig. 17A). The high flexibility and excellent shape recovery could be ascribed to structural characteristics such as an interlocked host structure without slip planes, weaker and dispersive interactions in the crystal, and mobile methanol solvent channels (Fig. 17B).

Furthermore, Mei and coworkers\textsuperscript{142} reported a 2:1 cocrystal of vitamin D and cholesterol with spring-like hydrogen bond networks, which formed through self-assembly of \textgamma-OH and \textalpha-OH–substituted cyclohexanol derivatives. In this system, the supramolecular interacting helix could sustain macroscopic flexibility throughout amplifying the elastic “spring” from many length scales. When impacting three-point local pressure on the (100) face, reversible bending occurred due to the region of “structural buffering” of the soft alkyl chains and exhibited a spring-like skeleton accompanied by looser packing (d = 2.10 Å) along the direction of hydrogen bond interactions. Hence, this face could accommodate specific stress without the occurrence of permanent slippage of molecules. Simultaneously, irreversible deformation on the (001) planes was observed because layers glide each other and without any alternation of

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure12.png}
\caption{(A) Chemical structure and photoisomerization of EPR upon exposure to light. (B) The hydrogen bond architectures of EPR–BET cocrystal. (C) The color change of EPR and EPR–BET cocrystal before and after irradiation. (D) Whole and partial reaction cavity of EPR form I (a, b, e, f) and EPR–BET cocrystals (c, d, g, h). Adapted from the Ref. 104 with the permission. Copyright © 2018 American Chemical Society.}
\end{figure}
3.4. Optical properties

The optical properties of drugs could be useful in biomedical applications. For example, drugs that exhibit strong fluorescence can be used as biocompatible probes for bioimaging and lipid droplet imaging in cells and in tissue slices. The molecular stacking, crystal packing arrangement and intermolecular interactions usually play important roles in the optical properties of solid materials. Recently, cocrystal engineering has shown its potential to modify the optical properties of pharmaceuticals. The following examples shows the modification of the optical behavior of drugs by introducing coformers into the crystal lattices.

The colorless furosemide (FS) is a BCS IV drug for the treatment of edema and hypertension. The polymorphic cocrystals of FS and 4,4'-bipyridine (4BPY, colorless) were pale yellow and orange for form I and form II, respectively (Fig. 18A and B). Both polymorphs have a similar sandwich centrosymmetric structure, formed by aromatic \( \pi \cdot \pi \) stacking interactions in the form of an “FS-4BPY-FS” arrangement (Fig. 18C). In form I, the sandwich motif comprises the C-H-\( \pi \) interactions between the H atom of 4BPY and the \( \pi \) electrons of the furan, as well as the \( \pi \cdot \pi \) interactions between FS and 4BPY. In form II, \( \pi \cdot \pi \) interactions and C=O-\( \pi \) interactions are engaged in the sandwich assembly. The authors proposed that the different \( \pi \)-stacking patterns and hydrogen bonding interactions in the polymorphs lead to differences in color. The HOMO (highest occupied molecular orbital) and LUMO (lowest unoccupied molecular orbital) gaps of cocrystals were further calculated by the DFT (density functional theory) simulation, which revealed that the band...
gap of form II was lower than that of form I, accounting for the different colors of two polymorphs.150

Emodin (EM) is a natural pigment with several pharmacological activities, such as anti-inflammatory, cathartic, anticancer and antioxidative activities. The color of EM was tuned from yellow to dark red by cocrystallization with a series of colorless coformers.149 Li et al.149 argued that π⋯π and charge-transfer interactions contribute to the color transit from yellow to red.

Figure 14  (A) Chemical structures of MD and its photoproducts. (B) Change in physical appearance of MD and its three cocrystals with an illumination of 4500 lux for 5 days. Adapted from the Ref. 114 with the permission. Copyright © 2016 American Chemical Society.

Figure 15  (A) The chemical structure of caffeine and glutaric acid. (B) Representative $P$–$h$ curves of the caffeine–glutaric acid cocystal. Blue arrows represent pop-in. (C) Crystal structure of form I and form II and a pictorial representation of softness–hardness modulation. Adapted from the Ref. 131 with the permission. Copyright © 2020 American Chemical Society.
The stronger $\pi \cdots \pi$ interactions could promote the charge-transfer process from the excited state to the ground state, leading to a redshift in the maximum absorption wavelength.

Phloretin (PHL), a natural phenol, has attracted attention from researchers due to its antioxidative and anti-inflammatory effects. Cocrystals of PHL with nicotinamide (NIC) and isonicotinamide (INM) exhibit different emission properties. Under 365 nm ultraviolet (UV) irradiation, the phloretin–nicotinamide (PHL–NIC) cocrystal shows the strong yellowish-green fluorescence, while no fluorescence of the phloretin–isonicotinamide cocrystal (PHL–INM cocrystal) is observed (Fig. 19). The distinct photoluminescent properties between PHL–NIC cocrystal and PHL–INM cocrystal could be attributed to the different packing arrangement and intermolecular interactions of PHL and coformers.

3.5. Bioavailability

Bioavailability refers to the fraction of the drug that reaches systemic circulation. Numerous drug candidates failed in the preclinical stage during drug development because of the low bioavailability. In the last decade, cocrystallization has shown its potential to improve in vivo performance by enhancing the solubility, and bioavailability of poorly water-soluble drugs.

Figure 16 (A) Chemical structure of celecoxib and L-proline. (B) Sticking propensity and (C) sticking layer thickness of celecoxib form III and celecoxib–L-proline cocrystal formulations (20% active in the MCC matrix) at compaction pressures of 100 and 250 MPa. Adapted from the Ref. 134 with the permission. Copyright © 2020 American Chemical Society.

Figure 17 (A) Image of elastic bending of cocrystal solvate: (a–f) first bending cycle by a pair of forceps and a metal pin; (g) crystal shape recovery after withdrawing the mechanical force; (h) second bending cycle; (i) the breaking of crystal when applied stress exceeded the elastic limit. (B) Interlocked structure (blue) and mobile methanol solvent channels (red). Adapted from the Ref. 140 with the permission. Copyright © 2012 John Wiley and Sons.
This strategy is especially suitable for drugs unable to form salts due to the lack of ionizable functional groups.

Ketoconazole, a broad-spectrum imidazole antifungal agent, exhibits low bioavailability because of its very low water solubility. The cocrystal of ketoconazole–p-aminobenzoic acid showed 10-fold higher aqueous solubility and 6.7-fold higher oral bioavailability than crystalline ketoconazole\(^{156}\). Apigenin (APG) is a bioflavonoid with many pharmacological activities, such as anti-inflammatory, anticarcinogenic and antibiotic properties\(^{157}\). However, the clinical application of APG is limited due to its extremely low solubility and bioavailability. The cocrystal of APG and 4,4'-bipyridine yielded 3.9-fold higher bioavailability than the parent drug\(^{157}\). Another sample, ambrisentan (AMT), is an endothelin type A receptor blocker and is approved for the treatment of pulmonary arterial hypertension\(^{158}\). The poor water solubility (0.06 mg/mL) of AMT categorizes it as a compound of BCS class II\(^{158}\). The cocrystal of AMT with glycylglycine (GG) is constructed by the supramolecular synthon networks, the carbonyl in AMT interact with OH\(_{acid}\) groups of GG (C=O-⋅OH\(_{acid}\)) as well as OH\(_{acid}\) of another AMT molecule, leading to the bifurcated C=O-⋅HO\(_{acid}\) interactions. The cocrystal of AMT-GG shows 2.7-fold enhancement of \(C_{\text{max}}\) (maximum plasma concentration) and nearly 2-fold increase in the value of AUC (area under plasma concentrations–time curve) in comparison with pure AMT\(^{158}\).

Baicalein is a well-known flavonoid with various pharmacological activities, such as antibacterial, anti-inflammatory, antiadipogenic, anticancer, and anti-HIV activities\(^{154}\). Unfortunately, the bioavailability of baicalein is quite low largely due to its poor water solubility (16 µg/mL). Cocrystal of baicalein with caffeine exhibited the superior pharmacokinetic property, the relative bioavailability of the cocrystal was enhanced by 4-fold in comparison with neat baicalein or physical mixtures on the basis of AUC0–24 h\(^{154}\).

The solution-mediated phase transformation may occur during the dissolution process of highly soluble cocrystals, in which the poorly soluble drugs precipitate out of solutions, diminishing the solubility advantage of cocrystals. This problem means that cocrystallization does not always have the positive effect on the solubility and bioavailability of the drugs. Thus, delaying or eliminating the process of solution-mediated phase transformation is essential to prolong the supersaturation for enhancing the bioavailability of poorly water-soluble drugs\(^{151,159}\). Childs et al.\(^{151}\) reported that the cocrystal of danazol–vanillin yielded only a 1.7 times higher AUC than the parent drug. However, over 10-fold improvement in oral bioavailability was achieved for the cocrystal dissolved in the presence of a solubilizing agent (1% vitamin E-TPGS) and a crystallization inhibitor (2% Klucel), where the supersaturation was maintained. Carbamazepine–succinic acid cocrystals underwent rapid phase transformation to the low-soluble parent drug during the dissolution process\(^{160}\). The bioavailability of carbamazepine–succinic acid cocrystals was improved by impeding the precipitation of carbamazepine using 1% hydroxypropylmethylcellulose acetate succinate (HPMCAS) and 2% polyvinyl caprolactam-polyvinyl acetate polyethylene glycol graft copolymer\(^{160}\) as crystallization inhibitors. Approximately 6-fold enhancement in AUC and 4-fold enhancement in \(C_{\text{max}}\) were achieved in comparison with the unformulated “neat” cocrystal. In addition, surfactants may have significant impacts on maintaining the supersaturation created by dissolution of cocrystals\(^{161}\). Alhalaweh et al.\(^{161}\) studied the effect of the surfactant (sodium lauryl sulfate) on the dissolution of carbamazepine–saccharin cocrystal and found that the surfactant could act as a

![Figure 18](image-url)
solubilizing agent to increase the solubility of the drug, which turned out to prolong the supersaturation by reducing the driving force of crystallization. Rodríguez-Hornedo and coworkers also demonstrated that the surfactant could decrease the solubility advantage (solubility_{cocrystal}/solubility_{drug}) of indomethacin–saccharin cocrystal and sequentially sustain the supersaturation. The increased solubility of the drug in the presence of surfactant lowered the driving force of nucleation, and thus the recrystallization was less favorable.

### 3.6. Sustained release

The sustained release dosage form exhibits considerable advantages in reduced dosing frequency, improved patient compliance, and mitigated side effects due to the steady-state blood level with less plasma fluctuations. Various formulation strategies have been used to achieve sustained release profiles, such as polymeric matrices, membrane-controlled and osmotic pump drug delivery systems. In the recent years, cocrystallization has been demonstrated as an alternative approach to sustain the drug release. For example, the half-life of nicorandil (NCD) was prolonged by cocrystallizing with poorly soluble organic acids, such as 1-hydroxy-2-naphthoic acid (1-HNA) and salicylic acid (SA). The NCD–1-HNA cocrystal displayed a reduction in the dissolution rate by approximately 22.7, 21.6 and 7.4 times in pH 2.0, 4.6, and 6.8 buffer, respectively, compared with pure NCD. The cocrystal of zonisamide with caffeine and L-proline exhibited a lower solubility and dissolution rate than pure zonisamide, indicating the potential for developing sustained-release formulations of zonisamide to solve the problem of half-life fluctuations. In addition, the sulfonamide class drugs sulfa methazole and sulfacetamide have unsatisfactory bioavailability due to their short in vivo elimination half-lives. For the drugs with fast systemic elimination, forming the cocrystals with lower equilibrium solubility and intrinsic dissolution rates could potentially serve as the approach to release the drugs sustainedly, resulting in the enhanced bioavailability.

Isoniazid (INH) is one of the first-line drugs for tuberculosis, which requires a large dose for long-term treatment, resulting in poor patient compliance, severe side effects of hepatotoxicity and drug resistance. Xuan et al. successfully developed an extended release form of isoniazid by cocrystallizing it with a hydrophobic coformer (curcumin). It has been reported that the thermodynamic solubility of cocrystals is related to the solubility of coformers, in which a lower soluble coformer could produce a cocrystal with low water solubility. Hence, the isoniazid–curcumin cocrystal has the low solubility by incorporating the poor soluble curcumin molecule into the same crystalline lattice. At pH 1.2, INH was completely released from the physical mixture after 15 min. However, only 28% of INH was dissolved from the cocrystal after 15 min, followed by sustained release, in which 73% of INH was released after 48 h. The authors attributed the reduced dissolution rate of the INH cocrystal to two reasons: (1) the introduction of low watersoluble curcumin (CUR) into the INH crystal lattice would block the solvation sites of IHN, thereby reducing its release rate; (2) CUR form III precipitated out of solution and covered at the cocrystal surface to inhibit the dissolution of INH from cocrystals. In contrast, INH was completely released after 24 h in pH 6.8 solution. The distinct release behaviors between different pH values are due to the different recrystallization kinetics of CUR.

Yu et al. studied the factor of cocrystal structure on influencing the release profiles of piperazine ferulate salt (PRZ–FLA), which has been used for treating kidney diseases. However, the short plasma half-life of PRZ–FLA render it difficult to achieve therapeutic plasma levels by the oral administration. A ternary cocrystal (piperazine–ferulate–pyrazinamide, PRZ–FLA–PRA) was designed to achieve the sustained release of drugs. In the structure of PRZ–FLA–PRA cocrystal, the PRZ–FLA connected...
with PRA dimers by the strong hydrogen bonding interactions to form a tight network (Fig. 21B). The hydrophilicity of PRZ–FLA was significantly decreased after forming the cocrystal since the solvation sites of PRZ–FLA was reduced from the structural perspective. The solubility of PRZ–FLA from cocrystals were lower than those of pure PRZ–FLA in different dissolution media at pH 1.2, 4.0 and 6.8 (Fig. 21C). As expected, the intrinsic dissolution rate of the PRZ–FLA salt decreased upon forming the ternary PRZ–FLA–PRA cocrystal (Fig. 21D).

The solubility APIs are correlated with lattice stabilities and intermolecular interactions in crystals. Kumari et al. demonstrated that the solubility and dissolution rate of pirfenidone (PFD) would be decreased by cocrystallizing with a suitable coformer to increase the crystal lattice and intermolecular interaction energy (Fig. 22). PFD is a new drug molecule used for healing idiopathic lung fibrosis (approved by the FDA in 2014). The high-dose pirfenidone shows serious side effects. The cocrystals of pirfenidone–fumaric acid (PFD–FA) and pirfenidone–trimesic acid (PFD–TA) yielded 50% and 90% reduced solubility of PFD, respectively. The solubility of PFD followed the order PFD > PFD–FA cocrystal > PFD–TA cocrystal, which was consistent with the observation that $E_{\text{lattice}}$ (PFD–FA cocrystal) > $E_{\text{lattice}}$ (PFD) as well as that $E_{\text{bind}}$ (PFD–TA cocrystal) > $E_{\text{bind}}$ (PFD–FA cocrystal). The authors proposed that the strong intermolecular force of cocrystals yielded high heat of fusion and hence reduced cocrystal solubility.

### 3.7. Therapeutic effect

The therapeutic effect of a drug substance is often influenced by its physicochemical properties. The limitation of low solubility or permeability of BSC II and BCS IV class drugs would immensely restrict the therapeutic effect of the medicines. The cocrystal strategy has been considered an effective technique to improve bioavailability and thus enhance the therapeutic effect. Table 2 shows a summary of reported cocrystals with enhanced therapeutic effects. Yu et al. studied the anticancer activities of tegafur after forming the cocrystal with a nutraceutical component, syringic acid (Fig. 23). In vitro cytotoxicity testing showed that tegafur–syringic acid cocrystals (TF–SYA cocrystal) had an enhanced inhibitory effect on different cancer cell lines (Fig. 23C). The improved solubility and dissolution rate of tegafur by the cocrystal were beneficial for generating higher drug concentrations near the tumor cells, thus impeding proliferation. In addition, the permeability of tegafur was enhanced by the cocrystal, which allowed more drugs to penetrate the cytomembrane of tumor cells.

5-Fluorouracil (FU) is a classic anticancer drug for treating stomach, breast, lung and colorectal cancers. Therapeutic effect of 5-fluorouracil was limited by the poor permeability and first-pass hepatic metabolism of the drug. Therefore, massive doses are required to maintain the therapeutic window of FU, with the resulting risk of side effects of drug resistance. Recently, several 5-fluorouracil cocrystals with the enhanced anticancer bioactivity have been successfully prepared with coformers, such as L-phenylalanine, cinnamic acid, piperazine, gentisic acid, 3,4-dihydroxybenzoic acid, 4-aminopyridine and hydroquinone. For instance, the cocrystal of 5-fluorouracil–L-phenylalanine (FU–PHE) exhibited greater anticancer activity in comparison with the individual components (Fig. 24). The IC50 values of the FU–PHE cocrystal were significantly decreased in comparison with those of the pure FU and the FU–PHE physical mixture (Fig. 24C). The lowest IC50 value of cocrystals against HCT-116 cells was 2.56 µmol/L after 72 h of testing, which was approximately 4 times lower than that of pure 5-FU and the physical mixture. The

---

**Figure 20**  (A) Chemical structure of isoniazid and curcumin. (B) Dissolution profile of INH from different sample groups in pH 1.2 buffer solution. (C) Dissolution profile of INH from 2:1 INH–CUR cocrystals in the presence of RIF in pH 1.2 and 6.8 buffer solutions ($n = 3$). NOTE: RIF represents rifampicin. Adapted from the Ref. 173 with the permission. Copyright © 2020 American Chemical Society.
improved anticancer inhibition effect of FU–PHE contributes to the enhanced solubility, dissolution rate, permeability and increased tumor cell targeting of 5-FU in the presence of PHE, which is one of the essential amino acids for tumor cell growth.

Sulfamethazine (STH) is a sulfonamide drug that is a widely used antibacterial drug for treating humans and animals. Recently, Pan and coworkers studied the antibacterial effect of the STH cocrystals (Fig. 25). p-Aminobenzoic acid (PABA) was selected as the coformer, forming a 1:1 cocrystal with STH by the slow evaporation crystallization method. Fig. 25B shows the antibacterial effect of the STH, PABA, physical mixture and sulfamethazine–p-aminobenzoic acid cocrystal (STH–PABA cocrystal) on Escherichia coli, a type of prokaryotic bacteria. The growth of E. coli was considerably inhibited in the group of the STH cocrystals (Fig. 25).

Figure 21  (A) The chemical structure of piperazine, ferulic acid, pyrazinamide. (B) The crystal structure of piperazine–ferulate–pyrazinamide cocrystal. (C) Solubility testing of piperazine ferulate salt (PRZ–FLA), cocrystal and pyrazinamide (PRA). (D) Intrinsic dissolution rate (IDR) testing of piperazine ferulate salt (PRZ–FLA), cocrystal and pyrazinamide (PRA) at pH 1.2. Adapted from the Ref. 165 with the permission. Copyright © 2020 American Chemical Society.

Figure 22  Chemical structure of pirfenidone (PFD), fumaric acid (FA) and trimesic acid (TA); hydrogen bonding between the PED–FA cocrystal and PFD–TA cocrystal; solubility results of the PFD, PFD–FA and PFD–TA cocrystals. Adapted from the Ref. 175 with the permission. Copyright © 2019 American Chemical Society.
Table 2  List of cocrystals with enhanced therapeutic effect.

| Therapeutic category | API              | Coformer                     | Ref.   |
|----------------------|------------------|------------------------------|--------|
| Anticancer           | Tegafur          | Syringic acid                | 179    |
|                      | 5-Fluorouracil   | L-Phenylalanine              | 180    |
|                      |                  | Cinnamic acid                | 181    |
|                      |                  | Piperazine                   | 182    |
|                      |                  | Gentisic acid                | 176    |
|                      |                  | 3,4-Dihydroxybenzoic acid    | 176    |
|                      |                  | 4-Aminopyridine              | 176    |
|                      |                  | Hydroquinone                 | 183    |
|                      | Quinoloxine      | 3-Thiosemicarbazone-butano-2-one-oxime | 189 |
|                      | Benztrotiazole   | p-Hydroxybenzoic acid        | 190    |
|                      | Temozolomide     | Oxalic acid                  | 191    |
|                      | Quercetin        | Pyrazole                     | 192    |
|                      |                  | Imidazolidinonone            | 192    |
|                      |                  | Baclofen                     | 192    |
|                      | Metformin        | Dichloroacetate              | 193    |
|                      | Dabrafenib       | Ethylenediamine hydrate      | 194    |
|                      | Berberine Chloride| Myricetin                   | 195    |
|                      | Betulinic acid   | Ascorbic acid                | 196    |
| Antibacterial        | Nitrofurantoin   | Trimethoprim                 | 197    |
|                      | Ciprofloxacin    | Carvacrol                    | 198    |
|                      |                  | Thymol                       | 198    |
|                      | Sulfathiazole    | Amantadine hydrochloride     | 177    |
|                      | Enoxacin         | Malonic acid                 | 199    |
|                      |                  | Oxalic acid                  | 199    |
|                      |                  | Fumaric acid                 | 199    |
|                      | Trimesic acid    | Theophylline                  | 200    |
|                      |                  | Caffeine                     | 200    |
|                      | Isothalic acid   | Caffeine                     | 200    |
|                      | Urotropine       | Syringic acid, trans-Cinnamic acid | 201   |
|                      | Sulfamethazine   | 4-[4-(Trifluoromethyl) phenoxy] phenol | 201 |
|                      | Sulfaguanidine   | Thiobarbutaric acid          | 202    |
|                      | Sulfamidimide    | 4-Aminosalicylic acid        | 203    |
|                      | Genistein        | 4,4'-Bipyridine              | 204    |
|                      | Benztrotiazole   | p-Hydroxybenzoic acid        | 190    |
|                      | Caffeine         | O-Formylphenoxyacetic acid monohydrate | 205 |
|                      |                  | p-Formylphenoxypropionic acid| 205    |
|                      | Betulinic acid   | Ascorbic acid                | 196    |
| Hepatoprotective     | Isoniazid        | Syringic acid                | 206,207|
|                      |                  | Quercetin                    | 185,206|
|                      | Pyrazinamide     | Quercetin                    | 178    |
|                      | Rifazole         | Syringic acid                | 208    |
| Arthritis            | Diacerein        | Isonicotinamide              | 209    |
|                      |                  | Nicotinamide                 | 209    |
|                      |                  | Theophylline                 | 209    |
|                      | Aceclofenac      | Lysine                       | 210    |
|                      | Hesperetin       | Picolinic acid               | 186    |
|                      |                  | Nicotinamide                 | 186    |
|                      |                  | Caffeine                     | 186    |
|                      | Chrysin          | Cytosine                     | 211    |
|                      |                  | Thiamine hydrochloride       | 211    |
| Antihemolytic        | Hesperetin       | Picolinic acid               | 186    |
|                      |                  | Nicotinamide                 | 186    |
|                      |                  | Caffeine                     | 186    |
|                      | Chrysin          | Cytosine                     | 211    |
|                      |                  | Thiamine hydrochloride       | 211    |
|                      | Quercetin        | Nicotinamide                 | 187    |
|                      |                  | Picolinic acid               | 187    |
| Anti-diabetes        | Glibenclamide    | Hippuric acid                | 188    |
|                      |                  | Nicotin acid                 | 188    |
|                      |                  | Theophylline                 | 188    |
|                      |                  | Succinic acid                | 188    |
|                      | Nateglinide      | Sucralose                    | 212    |
|                      | Gliclazide       | Sebacic acid                 | 213    |
cocrystal, with 2-fold higher antibacterial activity than that of pure STH at concentrations of 50 and 100 μg/mL. These results suggest that the enhanced antibacterial activity is due to the increased solubility of the cocrystals. As shown in Fig. 25C, the cell wall was intact with only several leaked cells in STH and PABA solutions after 12 h. However, the bacterial profile was significantly damaged in cocrystal solution, indicating that the leakage of cells would be enhanced by the STH–PABA cocrystal and thus drastically improve the antibacterial properties.

Long-term administration of high-dose isoniazid (INH) will cause severe liver injury for patients. The hepatotoxicity of INH is due to the generation of extremely high reactive oxygen species, which induce lipid peroxidation and eventually harm the cell membrane. Liu et al. studied in vivo hepatotoxicity testing of

---

**Figure 23** (A) Chemical structures of tegafur and syringic acid. (B) Crystal structure of tegafur–syringic acid cocrystal. (C) Cytotoxicity evaluation of individual materials, the cocrystal and physical mixture against the three tumor cell strains HCT-116 (human colon cancer), MDA-MB-231 (breast cancer) and MGC-803 (human gastric carcinoma) by sflorhodamine beta (SRB) assays. Note: a–c represent the CI values of the cocrystal of 0.79, 0.71, and 0.67 for HCT-116, MGC-803, and MDA-MB-231 tumor cell lines, respectively. *P < 0.05. Adapted from the Ref. 179 with the permission. Copyright © 2020 Royal Society of Chemistry.

---

**Figure 24** (A) Chemical structures of 5-fluorouracil (Fu) and L-phenylalanine (Phe). (B) Crystal structure of 5-fluorouracil–L-phenylalanine cocrystal and (C) IC₅₀ values (μmol/L) for the cell lines after 48 and 72 h exposure to the tested samples; note: HCT-116 (human colon cancer), MGC-803 (human gastric carcinoma), MCF-7 (human breast cancer), and A549 (human lung adenocarcinoma) were tested by SRB assay. Adapted from the Ref. 180 with the permission. Copyright © 2020 Royal Society of Chemistry.
untreated control, INH, a physical mixture of INH and quercetin (QCT) and isoniazid–quercetin cocrystal (INH–QCT cocrystal, Fig. 26). The total antioxidant states (TA), the level of aspartate aminotransferase (ASA) and alanine aminotransferase (ALA) of the four groups were measured after 3 days of treatment (Fig. 26B). For TA level testing, the cocrystal showed comparable value with the control group while the value of INH and the physical mixture group were lower in comparison with the control group, indicating that the cocrystal would improve the antioxidant effect of QCT to prevent the occurrence of hepatotoxicity during INH treatment. In addition, the levels of ASA and ALA were dramatically elevated after treatment with INH and the physical mixture because of the hepatotoxicity of INH. However, the values of ASA and ALA were similar to those in the control group in the cocrystal group. All results indicate that the cocrystallization of INH and QCT is effective in reducing INH-induced hepatotoxicity.

Chadha et al. studied the antihemolytic effects of the cocrystals of nutraceutical hesperetin (HESP) with different

Figure 25  (A) Chemical structures of sulfamethazine (STH) and \( p \)-aminobenzoic acid (PABA). (B) Antibacterial effect of STH, PABA, physical mixture and STH–PABA cocrystal on \( E. \ coli \). Different letters within the figure denote a significant difference (\( P < 0.05 \)). (C) Transmission Electron Microscopy (TEM) images of \( E. \ coli \) before (a) and after treatment with 500 \( \mu \)g/mL STH (b), PABA (c), and cocrystals (d) for 12 h. Adapted from the Ref. 184 with the permission. Copyright © 2019 American Chemical Society.

Figure 26  (A) Crystal structure of INH–QCT cocrystals and (B) protective effects of QCT against INH in cocrystals and mixtures detected by serum TA and liver enzyme levels in rats (\( n = 6 \)). Adapted from the Ref. 185 with the permission. Copyright © 2020 Elsevier.
coformers, picolinic acid, nicotinamide, and caffeine. The cocrystals exhibited greater inhibition of hemolysis of rat RBSs than pure hesperetin (Fig. 27A). The inhibition effect of the samples is in the order hesperetin-caffeine cocrystal (HESP–CAF) > hesperetin-nicotinamide cocrystal (HESP–NIC) > hesperetin–picolinic acid cocrystal (HESP–PICO) > HESP. The maximum value of inhibition of hemolysis by HESP–CAF is 60%, followed by HESP–NIC (40%) and HESP–PICO (30%)178. Additionally, the cocrystals of quercetin–nicotinamide cocrystal (QCT–NIC) and quercetin–picolinic acid cocrystal (QCT–PICO) also displayed better antihemolytic activity than the pure substance (Fig. 27B)187. The percent inhibition of hemolysis in QCT–PICO and QCT–NIC was 3 and 2 times that of pure QCT, respectively187. The improved antihemolytic activity of cocrystals is linked to their higher solubilities and dissolution rates187.

Glibenclamide (GCM) is a BCS class II drug for the treatment of type II (noninsulin-dependent) diabetes; it is a second-generation sulfonyl urea that has low solubility but high permeability. The plasma glucose levels of the rats in different systems were evaluated in protein-free plasma by enzymatic glucose oxidase peroxidase after 7 days of oral administration (Fig. 28)188. The maximum value of glucose reduction was up to 93.68% for glibenclamide–succinic acid cocrystal (GCM–HA), 53.68% for glibenclamide–theophylline cocrystal (GCM–TP) and 40.68% for GCM188.

4. Concluding remarks and future perspectives

In the past decade, cocrystal engineering has become a promising approach to improve the performance of drug substances by modifying their undesired physicochemical properties. Large numbers of pharmaceutical cocrystals have been reported, and some of them have been approved by the FDA or in the clinical trials29. Nevertheless there are still some considerable challenges for developing cocrystals into commercial drug products.

In designing a pharmaceutical cocrystal, it is critical to select a suitable coformer. However, the selection of coforms has still largely relied on trial and error, which is time consuming and labor-intensive. Recently, a variety of computer-assisted approaches have emerging as attractive tools to accelerate the screening process of cocrystals214–218. For example, the artificial neural network models are developed to predict cocrystal formation by analyzing a network of coformers extracted from the Cambridge Structural Database (CSD)218.

An enhanced understanding of the structure-based physicochemical properties is critical for the rational design of cocrystals with desired functions and performances. In addition, the compatibility between cocrystals and other excipients, pharmacokinetic
profiles, therapeutic efficacy and toxicity issues should be carefully taken into consideration in developing the formulation of cocrystal. Another hurdle for commercialization is the scale-up of high-purity pharmaceutical cocrystals. Continuous process is emerging as a new paradigm in high-throughput manufacture of pharmaceutical materials. The twin-screw extrusion integrated with process analytical tools for in-line process control has been attempted to produce high quality cocrystals \(^{20,22}\).

In conclusions, this review provides detailed description and examples about preparation methods, physicochemical properties and various applications of cocrystals. The innovative technologies along with the comprehensive regulatory guidance will advance the translational development of pharmaceutical cocrystals for healthcare applications. More cocrystal-based drug products are believed to be commercially available for patients in the future.

Acknowledgments

The authors are grateful for the financial support to this work from the National Natural Science Foundation of China (Nos. 81872813), the Outstanding Youth Fund of Jiangsu Province of China (BK20190029), Natural Science Foundation of Jiangsu Province (BK 20200576, China), Fundamental Research Funds for the Central Universities (No. 2632020PY04) and the Program of State Key Laboratory of Natural Medicines-China Pharmaceutical University (No. SKLNZZ202031).

Author contributions

Minshan Guo summarized the literatures and drafted the manuscript with the assistance of Xiaojie Sun and Jiahui Chen. Ting Cai conceived, supervised and edited the review. All of the authors have read and approved the final manuscript.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Cerreia Vioglio P, Chierotti MR, Gobetto R. Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges. \textit{Adv Drug Deliv Rev} 2017;117:86–110.
2. Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. \textit{Acta Pharm Sin B} 2015;5:442–53.
3. Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. \textit{Cryst Growth Des} 2009;9:2950–67.
4. Datta S, Grant DJW. Crystal structures of drugs: advances in determination, prediction and engineering. \textit{Nat Rev Drug Discov} 2004;3:42–57.
5. Umeda Y, Fukami T, Furuiishi T, Suzuki T, Tanjoh K, Tomono K. Characterization of multicomponent crystal formed between indomethacin and lidocaine. \textit{Drug Dev Ind Pharm} 2009;35:843–51.
6. Karpinski PH. Polymorphism of active pharmaceutical ingredients. \textit{Chem Eng Technol} 2006;29:233–7.
7. Khankari RK, Grant DJW. Pharmaceutical hydrates. \textit{Thermochim Acta} 1995;248:61–79.
8. Healy AM, Woruk ZA, Kumar D, Madi AM. Pharmaceutical solvates, hydrates and amorphous forms: a special emphasis on cocrystals. \textit{Adv Drug Deliv Rev} 2017;117:25–46.
9. Remenar JF, Morissette SL, Peterson ML, Mouton B, Macphee JM, Guzman HR, et al. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. \textit{J Am Chem Soc} 2003;125:8456–7.
10. Duggirala NK, Perry ML, Almarsson Ö, Zaworotko MJ. Pharmaceutical cocrystals: along the path to improved medicines. \textit{Chem Comm} 2015;52:640–55.
11. Yousef MAE, Vangala VR. Pharmaceutical co-crystals: molecules, crystals, formulations, medicines. \textit{Cryst Growth Des} 2019;19:7420–38.
12. Karimijafari M, Pedrela L, Walker G, Croker D. Creating cocrystals, a review of pharmaceutical cocrystal preparation routes and applications. \textit{Cryst Growth Des} 2018;18:6370–87.
13. Novartis Pharmaceuticals Corporation. Drug trials snapshot: ENTRESTO. Approval date: July 7, 2015. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-entresto.
14. Merck Sharpe & Dohme Corp. Drug trials snapshots: STEGLATRO. Approval date: December 19, 2017. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-steglatro.
15. Videla S, Lahjour M, Vaqué A, Sust M, Encabo M, Soler L, et al. Single-dose pharmacokinetics of co-crystal of tramadol–celexoxib: results of a four-way randomized open-label phase I clinical trial in healthy subjects. \textit{Br J Clin Pharmacol} 2017;83:2718–28.
16. Kimoto K, Yamamoto M, Karashima M, Hohokabe T, Takeda J, Yamamoto K, et al. Pharmaceutical cocrystal development of TAK-020 with enhanced oral absorption. \textit{Crystals} 2020;10:211–29.
17. Huang S, Xu J, Peng Y, Guo M, Cai T. Facile tuning of the photo-luminescence and dissolution properties of phloretin through cocrystalization. \textit{Cryst Growth Des} 2019;19:6837–44.
18. Walsh RDB, Bradner MW, Fleischman AS, Morales LA, Zaworotko MJ. Crystal engineering of the composition of pharmaceutical phases. \textit{Chem Comm} 2003;9:186–7.
19. Childs SL, Chylli LI, Dunlap JT, Smolenskaya VN, Stably BC, Stably GP. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoin, succinic, and fumaric acids. \textit{J Am Chem Soc} 2006;128:13335–42.
20. Fleischman SG, Kudova SS, Jennifer AM, Brian M, Walsh RDB, Rodríguez-Hornedo N, et al. Crystal engineering of the composition of pharmaceutical phases: multiple-component crystalline solids involving carbamazepine. \textit{Cryst Growth Des} 2003;3:909–19.
21. Vishweshwar P, McMahon JA, Peterson ML, Hickey MB, Shattock TR, Zaworotko MJ. Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients. \textit{Chem Comm} 2005;4601–3.
22. Zaworotko MJ. Molecules to crystals, crystals to molecules ... and back again?. \textit{Cryst Growth Des} 2007;7:4–9.
23. Shattock TR, Arora KK, Vishweshwar P, Zaworotko MJ. Hierarchy of supramolecular synths: persistent carboxylic acid···pyridine hydrogen bonds in cocrystals that also contain a hydroxyl moiety. \textit{Cryst Growth Des} 2008;8:4533–45.
24. Kale DP, Zode SS, Bansal AK. Challenges in translational development of pharmaceutical cocrystals. \textit{J Pharm Sci} 2017;106:457–70.
25. Guide for industry. Regulatory classification of pharmaceutical cocrystals. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); December 2011. Available from: https://www.fda.gov/media/38724/download.
26. Guide for industry. Regulatory classification of pharmaceutical cocrystals. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); August 2016. Available from: https://www.fda.gov/media/99917/download.
27. Guide for industry. Regulatory classification of pharmaceutical cocrystals. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); February 2018. Available from: https://www.fda.gov/media/81824/download.
28. EMA. Reflection paper on the use of cocrystals of active substances in medicinal products. 21 May 2015. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-cocrystals-active-substances-medicinal-products_en.pdf.
29. Kavanagh ON, Croker DM, Walker GM, Zaworotko MJ. Pharmaceutical cocrystals: from serendipity to design to application. Drug Discov Today 2019;24:796–804.
30. Kuminek G, Cao F, Bahia de Oliveira da Rocha A, Gonçalves Cardoso S, Rodríguez-Hornedo N. Cocrystals to facilitate delivery of poorly soluble compounds beyond-rul-of-5. Adv Drug Deliv Rev 2016;101:143–66.
31. Chiarella RA, Davey RJ, Peterson ML. Making co-crystals the utility of ternary phase diagrams. Cryst Growth Des 2007;7:1223–6.
32. Blagden N, Berry DJ, Parkin A, Javed H, Ibrahim A, Gavan PT, et al. Current directions in co-crystal growth. New J Chem 2008;32:1659–72.
33. Weyna DR, Shattock T, Vishweshwar P, Zaworotko MJ. Synthesis and structural characterization of cocrystals and pharmaceutical cocrystals: mechanismochemistry vs slow evaporation from solution. Cryst Growth Des 2009;9:1106–23.
34. Basavuso S, Boström D, Velaga SP. Pharmaceutical cocrystal and salts of norfl oxacin. Cryst Growth Des 2006;6:699–708.
35. Chow SF, Chen M, Shi L, Chow AHW, Sun CC. Simultaneously improving the mechanical properties, dissolution rate, hygroscopicity of ibuprofen and flurbiprofen by cocystalization with nicotinamide. Pharm Res (N Y) 2012;29:1854–65.
36. Modani S, Gunnam A, Yadav B, Nangia AK, Shastrī NR. Generation and evaluation of pharmacologically relevant drug–drug cocystal for gut therapy. Cryst Growth Des 2020;20:3577–83.
37. Nikam VJ, Patil SB. Pharmaceutical cocrystals of nebivolol hydrochloride with enhanced solubility. J Cryst Growth 2020;534:125488.
38. Rodrigues M, Baptista B, Lopes JA, Saragüeta MC. Pharmaceutical cocrystalization techniques. Advances and challenges. Int J Pharm 2018;547:404–20.
39. Wang IC, Lee MJ, Sim SJ, Kim WS, Chun NH, Choi GJ. Anti-solvent co-crystallization of carbamazepine and saccharin. Int J Pharm 2013;450:311–22.
40. Nishimaru M, Kudo S, Takiyama H. Cocystal production method reducing deposition risk of undesired single component crystals in anti-solvent cocystalization. J Ind Eng Chem 2016;36:40–3.
41. Lee MJ, Wang IC, Kim MJ, Kim P, Song KH, Chun NH, et al. Controlling the polymorphism of carbamazepine-saccharin cocrystals formed during anti-solvent cocystalization using kinetic parameters. Korean J Chem Eng 2015;32:1910–7.
42. Chun NH, Wang IC, Lee MJ, Jung YT, Lee S, Kim WS, et al. Characteristics of indomethacin–saccharin (IMC–SAC) co-cocrystals prepared by an anti-solvent crystallization process. Eur J Pharm Biopharm 2013;85:854–61.
43. Mullin JW. Crystallization. 4th ed. 2001. p. 536–75. Crystallization.
44. Yu ZQ, Chow PS, Tan RBH. Operating regions in cooling cocrystalization of caffeine and glutaric acid in acetonitrile. Cryst Growth Des 2010;10:2382–7.
45. Hickey MB, Peterson ML, Scoppettuolo LA, Morrisette SL, Vetter A, Guzmán H, et al. Performance comparison of a co-crystal of carbamazepine with marketed product. Eur J Pharm Biopharm 2007;67:112–9.
46. Sheikh AY, Rahim SA, Hammond RB, Roberts KJ. Scalable solution cocrystalization: case of carbamazepine-nicotinamide I. CrystEngComm 2009;11:501–9.
47. Leung DH, Lohani S, Ball RG, Canfield N, Wang Y, Rhodes T, et al. Two novel pharmaceutical cocrystals of a development compound—screening, scale-up, and characterization. Cryst Growth Des 2012;12:1254–62.
48. Zhao L, Raval V, Briggs NEB, Bhadrwaj RM, McGlone T, Oswald IDH, et al. From discovery to scale-up: α-lipoic acid: nicotinamide co-crystals in a continuous oscillatory baffled crystalliser. CrystEngComm 2014;16:5769–80.
49. Rodríguez-Hornedo N, Nehm SJ, Seefeldt KF, Pagán-Torres Y, Falkiewicz CJ. Reaction crystallization of pharmaceutical molecular complexes. Mol Pharm 2006;3:362–7.
50. Machado TC, Kuminek G, Cardoso SG, Rodríguez-Hornedo N. The role of pH and dose/solubility ratio on cocystal dissolution, drug supersaturation and precipitation. Eur J Pharm Sci 2020;152:105422.
51. Cao F, Amidon GL, Rodríguez-Hornedo N, Amidon GE. Mechanistic analysis of cocystal dissolution as a function of pH and micellar solubilization. Mol Pharm 2016;13:1030–46.
52. Maya P, Lipert Nair, Rodríguez-Hornedo. Cocystal transition points: role of cocystal solubility, drug solubility, and solubilizing agents. Mol Pharm 2015;12:3535–46.
53. Huang Y, Zhou L, Yang W, Li Y, Yin Q. Preparation of theophylline-henzoic acid cocystal and on-line monitoring of cocystalization process in solution by Raman spectroscopy. Crystals 2019;9:329–44.
54. Dai XL, Yao J, Wu C, Deng JH, Mo YH, Lu TB, et al. Solubility and permeability improvement of allopurinol by cocystalization. Cryst Growth Des 2020;20:5160–8.
55. Ouiyangkul P, Tantishayakul V, Hirun N. Exploring potential coformers for oxysrerotol using principal component analysis. Int J Pharm 2020;587:119630.
56. Yuan ZJ, Dai XL, Huang YL, Yu LB, Chen JN. Cocystals of penicilloyr with hydroxybenzoic acids: synthesis, crystal structures, and physicochemical evaluation. Cryst Growth Des 2020;20:4108–19.
57. Harfouche LC, Courvat N, Sanselme M, Brandel C, Coquerel G. Discovery of new proprxylphine based chiral cocrystals: solid state landscape and dehydration mechanism. Cryst Growth Des 2020;20:3842–50.
58. Nagapudi K, Umanzor EY, Masui C. High-throughput screening and scale-up of cocrystals using resonant acoustic mixing. Int J Pharm 2017;521:337–45.
59. Michalchuk AAL, Hope KS, Kennedy SR, Blanco MV, Boldyreva EV, Pulham CR. Ball-free mechanochimistry: in situ real-time monitoring of pharmaceutical co-crystal formation by resonant acoustic mixing. Chem Commun 2018;54:4033–6.
60. Am Ende DJ, Anderson SR, Salan JS. Development and scale-up of cocrystals using resonant acoustic mixing. Org Process Res Dev 2014;18:331–41.
61. Kaupp G. Solid-state molecular syntheses: complete reactions without auxiliaries based on the new solid-state mechanism. Cryst Growth Des 2003;5:117–33.
62. Maheshwari C, Javanskar A, Khan NA, Amidon GE, Rodríguez-Hornedo N. Factors that influence the spontaneous formation of pharmaceutical cocrystals by simply mixing solid reactants. Cryst Eng Commun 2009;11:493–500.
63. Macfinonhaile P, Crowley CM, Mcardle P, Erxleben A. Spontaneous solid-state co-crystalization of caffeine and urea. Cryst Growth Des 2020;20:736–45.
64. Ervasti T, Aaltenon J, Ketolainen J. Theophylline–nicotinamide cocystal formation in physical mixture during storage. Int J Pharm 2015;486:121–30.
65. Sarcevic I, Orola Ln, Nartowski KP, Khimiyak YZ, Round AN, Fäbián L. Mechanistic and kinetic insight into spontaneous cocystalization of isoniazid and benzonic acid. Mol Pharm 2015;12:2981–92.
66. Nartowski KP, Khimiyak YZ, Berry DJ. Tuning the spontaneous formation kinetics of caffeine: malonic acid co-cocrystals. Cryst Eng Comm 2016;18:2617–20.
67. Ji C, Hoffman MC, Mehta MA. Catalytic effect of solvent vapors on the spontaneous formation of caffeine–malonic acid cocystal. Cryst Growth Des 2017;17:1456–9.
68. Sarcevic I, Orola L, Belyakov S, Veidis MV. Spontaneous cocystal hydrate formation in the solid state: crystal structure aspects and kinetics. New J Chem 2013;37:2978–82.
69. Braga D, Gregioni F, Maini L, Prosperi S, Gobetto R, Chierotti MR. From unexpected reactions to a new family of ionic co-crystals: the
case of barbituric acid with alkali bromides and caesium iodide. Chem Commun 2010;46:7715–7.
70. Jayasankar A, Good DJ, Rodríguez-Hornedo N. Mechanisms by which moisture generates cocrystals. Mol Pharm 2007;4:360–72.
71. Huski J, Christopherson JC, Užarević K, Frisić T. In situ monitoring of vapour-induced assembly of pharmaceutical cocrystals using a benchtop powder X-ray diffractometer. Chem Commun 2016;52:5210–3.
72. Chadwick K, Davey R, Cross W. How does grinding produce co-crystals? Insights from the case of benzophenone and diphenylamine. Cryst EngComm 2009;11:1621–37.
73. Liu X, Lu M, Guo Z, Huang L, Feng X, Wu C. Improving the mechanism of co-crystal formation via grinding. Cryst Growth Des 2009;9:470–81.
74. Fischer F, Scholz G, Benemann S, Rademann K, Emmelting F. Evaluation of the formation pathways of cocrystal polymorphs in liquid-assisted syntheses. CrystEngComm 2014;16:8272–8.
75. Yang Y, Chen JM, Lu TB. Thermodynamics and preliminary pharmaceutical characterization of a melatonin–pimelic acid cocrystal prepared by a melt crystallization method. CrystEngComm 2015;17:4012–20.
76. Liu X, Lu M, Guo Z, Huang L, Feng X, Wu C. Improving the chemical stability of amorphous solid dispersion with co-crystal technique by hot melt extrusion. Pharm Res (N Y) 2012;29:806–17.
77. Seefeldt K, Miller J, Alvarez-Núñez F, Rodríguez-Hornedo N. Crystallization pathways and kinetics of carbamazepine–nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies. J Pharm Sci 2007;96:1147–58.
78. Guo C, Zhang Q, Zhu B, Zhang Z, Mei X. Drug–drug cocrystals provide significant improvements of drug properties in treatment with progesterone. Cryst Growth Des 2020;20:3053–63.
79. Baccich E, Capucci D, Giannetto M, Mattarozzi M, Pelagatti P, Rodriguez-Hornedo N, et al. Turning liquid propranolol into solid (without freezing it): thermodynamic characterization of pharmaceutical cocrystals built with a liquid drug. Cryst Growth Des 2016;16:6547–55.
80. Liu F, Hooks DE, Li N, Mara NA, Swift JA. Mechanical properties of anhydrous and hydrated uric acid crystals. Chem Mater 2018;30:3798–805.
81. Puñapeddi M, Serajuddin ATM. Trends in solubility of polymorphs. J Pharm Sci 2005;94:929–39.
82. Roy S, Quinones R, Matzger AJ. Structural and physicochemical aspects of dasatinib hydrate and anhydrate phases. Cryst Growth Des 2012;12:2122–6.
83. DENG JH, Lu TB, Sun CC, Chen JM. Dapagliflozin-citric acid cocrystal showing better solid state properties than dapagliflozin. Eur J Pharm Sci 2017;104:255–61.
84. Huang S, Xue Q, Xu J, Ruan S, Cai T. Simultaneously improving the physicochemical properties, dissolution performance, and bioavailability of apigenin and daidzein by co-crystallization with theophylline. J Pharm Sci 2019;108:2982–93.
85. Syed TA, Guika VG, Mukherjee S. Stability of co-crystals of caffeine with gallic acid in presence of coformers. J Food Process Eng 2019;42:e13066.
86. Shinozaki T, Ono M, Higashi K, Moribe K. A novel drug–drug cocrystal of levofloxacin and metametol: reduced hygroscopicity and improved photostability of levofloxacin. J Pharm Sci 2019;108:2383–90.
87. Trask AV, Motherwell WDS, Jones W. Pharmaceutical cocrystallization: engineering a remedy for caffeine hydration. Cryst Growth Des 2005;5:1013–21.
88. Chen X, Li D, Luo C, Wang J, Deng Z, Zhang H. Cocrystals of zileuton with enhanced physical stability. CrystEngComm 2018;20:990–1000.
89. Nugraha YP, Uekusa H. Suppressed hydration in metoclopramide hydrochloride by salt cocrystallisation. CrystEngComm 2018;20:653–62.
90. Wang ZZ, Chen JM, Lu TB. Enhancing the hygroscopic stability of S-oxiracetam via pharmaceutical cocrystals. Cryst Growth Des 2012;12:4562–6.
91. Boßl L, Sande DD, Barbas R, Prohens R. New cocrystal of ubiquinol with high stability to oxidation. Cryst Growth Des 2020;20:5583–8.
92. Guo C, Zhang Q, Zhu B, Zhang Z, Bao J, Ding Q, et al. Pharmaceutical cocrystals of nicothand with enhanced chemical stability and sustained release. Cryst Growth Des 2020;20:6995–7005.
93. Ohashi Y, Yanagi K, Kurihara T, Sasada Y, Ohgo Y. Crystalline state reaction of cobaloxime complexes by X-ray exposure. 1. Direct observation of cobalt–carbon bond cleavage in [(R)-1-cyanoethyl] (S)–(−)-alpha-methylbenzylamine[bis(dimethylglyoximato)cobal-(III)]. J Am Chem Soc 1981;103:5805–12.
94. Ramírez MA, Borja NL. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy 2008;28:646–55.
95. Putra OD, Umeda D, Nugraha YP, Nango K, Yonemochi E, Uekusa H. Simultaneous improvement of epalrestat photostability and solubility via cocrystallization: a case study. Cryst Growth Des 2018;18:373–9.
96. Steele JW, Faulds D, Goa KL. Epalrestat. A review of its pharmaceutical characterization, dissolution performance, and bioavailability. J Pharm Sci 2016;105:11538–49.
97. Chen X, Li D, Luo C, Wang J, Deng Z, Zhang H. Cocrystals of zileuton with enhanced physical stability. CrystEngComm 2018;20:990–1000.
98. Wang ZZ, Chen JM, Lu TB. Enhancing the hygroscopic stability of S-oxiracetam via pharmaceutical cocrystals. Cryst Growth Des 2012;12:4562–6.
99. Boßl L, Sande DD, Barbas R, Prohens R. New cocrystal of ubiquinol with high stability to oxidation. Cryst Growth Des 2020;20:5583–8.
100. Guo C, Zhang Q, Zhu B, Zhang Z, Bao J, Ding Q, et al. Pharmaceutical cocrystals of nicotinamide with enhanced chemical stability and sustained release. Cryst Growth Des 2020;20:6995–7005.
101. Ohashi Y, Yanagi K, Kurihara T, Sasada Y, Ohgo Y. Crystalline state reaction of cobaloxime complexes by X-ray exposure. 1. Direct observation of cobalt–carbon bond cleavage in [(R)-1-cyanoethyl] (S)–(−)-alpha-methylbenzylamine[bis(dimethylglyoximato)cobal-
110. Yuan LC, Dahl TC, Oliyai R. Effect of carbonate salts on the kinetics of acid-catalyzed dimerization of adefovir dipivoxil. *Pharm Res* 2000;17:1098–103 (N Y).

111. Lim RZ, Sun PJ, Tao Q, Yao J, Chen JM, Lu TB. Mechanism study on stability enhancement of adefovir dipivoxil by co-crystallization: degradation kinetics and structure-stability correlation. *Eur J Pharm Sci* 2016;85:141–8.

112. Gao Y, Gao J, Liu Z, Kan H, Zu H, Sun W, et al. Coformer selection based on degradation pathway of drugs: a case study of adefovir dipivoxil-saccharin and adefovir dipivoxil-nicotinamide co-crystals. *Int J Pharm* 2012;438:327–35.

113. Werbin H, Strom ET. Photochemistry of electron-transport quinones. *I. model studies with 2-methyl-1,4-naphthoquinone (vitamin K3).* *J Am Chem Soc* 1968;90:7296–301.

114. Zhu B, Wang JR, Zhang Q, Mei X. Improving dissolution and photostability of vitamin K3 via co-crystallization with naphthoic acids and sulfamerazine. *Cryst Growth Dev* 2016;16:483–92.

115. Teraoka R, Fukami T, Futuruishi T, Nagase H, Ueda H, Tode C, et al. Structure-mechanics and improved tableting performance of the drug forms and real-time solid-state fluorescence. *Mol Pharm* 2020;17:21–31.

116. Joshi T, Singaraju A, Shah H, Morris L, Haware R. Structure-mechanics and compressibility profile study of flufenamic acid-nicotinamide co-crystal. *Cryst Growth Dev* 2018;18:5853–65.

117. Bhatt JA, Bahl D, Morris K, Stevens LL, Haware RV. Structure-mechanics and improved tabletting performance of the drug–drug co-crystal metformin:salicicylic acid. *Eur J Pharm Biopharm* 2020;153:23–35.

118. Sun C, Grant DJW. Influence of crystal shape on the tabletting performance of 1-lysine monohydrochloride dihydrate. *J Pharm Sci* 2001;90:569–79.

119. Geng N, Chen JM, Li ZJ, Jiang L, Lu TB. Approach of cocrystalization with naphthoic acids and sulfamerazine. *Cryst Growth Dev* 2008;8:1575–9.

120. Bolla G, Nangia A. Pharmaceutical cocrystals: walking the talk. *Chem Comm* 2016;52:3342–60.

121. Mishra M, Mishra K, Narayan A, Reddy C, Vangala V. Structural basis for mechanical anisotropy in polymorphs of caffeine–glutamic acid co-crystal. *Cryst Growth Dev* 2020;20:6306–15.

122. Roy P, Ghosh A. Mechanochemical co-crystallization to improve the physicochemical properties of chloroxazone. *Cryst Eng Comm* 2020;22:4611–20.

123. Chattoraj S, Shi L, Chen M, Velaga S, Sun C. Origin of deteriorated mechanical properties of caffeine cocrystals: a polymorphic study. *Adv Mater* 2018;30:2930–40.

124. Yadav JP, Yadav RN, Uniyal P, Chen H, Jain S. Molecular intercalation of mechanical behavior in four basic crystal packing of isoniazid with homologous cocrystal formers. *Cryst Growth Dev* 2020;20:832–44.

125. Singaraju A, Bahl D, Wang C, Swenson D, Sun C, Stevens L. Molecular interpretation of the compaction performance and mechanical properties of caffeine cocrystals: a polymorphic study. *Mol Pharm* 2020;17:21–31.

126. Joshi T, Singaraju A, Shah H, Morris K, Stevens L, Haware R. Structure-mechanics and compressibility profile study of flufenamic acid-nicotinamide co-crystal. *Cryst Growth Dev* 2018;18:5853–65.

127. Bhatt JA, Bahl D, Morris K, Stevens LL, Haware RV. Structure-mechanics and improved tabletting performance of the drug–drug co-crystal metformin:salicicylic acid. *Eur J Pharm Biopharm* 2020;153:23–35.

128. Sun C, Grant DJW. Influence of crystal shape on the tabletting performance of 1-lysine monohydrochloride dihydrate. *J Pharm Sci* 2001;90:569–79.

129. Sun C, Hou H. Improving mechanical properties of caffeine and methyl gallate crystals by co-crystallization. *Cryst Growth Des* 2008;8:1575–9.

130. Bolla G, Nangia A. Pharmaceutical cocrystals: walking the talk. *Chem Comm* 2016;52:3342–60.

131. Mishra M, Mishra K, Narayan A, Reddy C, Vangala V. Structural basis for mechanical anisotropy in polymorphs of caffeine–glutamic acid co-crystal. *Cryst Growth Dev* 2020;20:6306–15.

132. Roy P, Ghosh A. Mechanochemical co-crystallization to improve the physicochemical properties of chloroxazone. *Cryst Eng Comm* 2020;22:4611–20.

133. Paul S, Taylor LJ, Murphy B, Krzyzaniak J, Dawson N, Mulluran MP, Meenan P, Sun CC. Mechanism and kinetics of punch sticking of pharmaceuticals. *J Pharm Sci* 2017;106:151–8.

134. Wang C, Paul S, Sun D, Nilsson Lill S, Sun C. Mitigating punch sticking propensity of celecoxib by co-crystallization: an integrated computational and experimental approach. *Cryst Growth Dev* 2020;20:4217–23.

135. Varughese PS, Mangalampalli K, Solonko K, Bond A, Ramamurty U, Desiraju G. Interaction anisotropy and shear instability of aspirin polymorphs established by nanoindentation. *Chem Sci* 2011;2:2236–42.

136. Lv S, Dudek DM, Cao Y, Balamurali MM, Goslione J, Li H. Designed biomaterials to mimic the mechanical properties of muscles. *Nature* 2010;465:69–73.

137. Hayashi S, Yamamoto Sy, Takeuchi D, Ie Y, Takagi K. Creating elastic organic crystals of π-conjugated molecules with bending mechanofluorochromism and flexible optical waveguide. *Angew Chem Int Ed* 2018;57:17002–8.

138. Bhattacharya B, Roy D, Dey S, Puthuvakkal A, Bhunia S, Mondal S, et al. Mechanical-bending-induced fluorescence enhancement in plastically flexible crystals of a GFP chromophore analogue. *Angew Chem Int Ed* 2020;59:19878–83.

139. Lai S, Temiño I, Cramer T, Del Pozo F, Fraboni B, Cosseddu P, et al. Morphology influence on the mechanical stress response in bendable organic field—effect transistors with solution—processed semiconductors. *Adv Electron Mater* 2017;4:1700271.

140. Ghosh S, Reddy CM. Elastic and bendable caffeine cocrystals: implications for the design of flexible organic materials. *Angew Chem Int Ed* 2012;51:10319–23.

141. Li S, Yan D. Tuning light-driven motion and bending in macroscale flexible molecular crystals based on a cocrystal approach. *ACS Appl Mater Interfaces* 2018;10:22703–10.

142. Wang JR, Li M, Yu Q, Zhang Z, Zhu B, Qin W, Mei X. Anisotropic mechanical properties of caffeine cocrystals: an interesting case of multi-component solids. *Cryst Eng Comm* 2018;20:1098–110.

143. Bhattacharya B, Roy D, Dey S, Puthuvakkal A, Bhunia S, Mondal S, et al. Mechanical-bending-induced fluorescence enhancement in plastically flexible crystals of a GFP chromophore analogue. *Angew Chem Int Ed* 2020;59:19878–83.

144. Gu Y, Zhao Z, Su H, Zhang P, Liu J, Niu G, et al. Exploration of biocompatible AIEgens from natural resources. *Chem Sci* 2018;9:6497–502.

145. Yan D, Evans DG. Molecular crystalline materials with tunable luminescent properties: from polymorphs to multi-component solids. *Mater Horiz* 2013;1:46–57.

146. Yang D, Delorai A, Lloyd GO, Frišič T, Day GM, Jones W, et al. A cocrystal strategy to tune the luminescent properties of stilbene-type organic solid-state materials. *Angew Chem* 2016;12:14283–6.

147. Wuest JD. Co-crystals give light a tune-up. *Nat Chem* 2010;2:74–75.

148. Walmart A, Schiefer J, Schobitz A, Dehning A, et al. Monitoring of their transformations using in situ monitoring of their transformations using solid-state fluorescence. *Cryst Eng Comm* 2013;15:5100–6.

149. Li M, Liu C, Zhang Q, Peng B, Zhu B, Wang JR, et al. Fine-tuning the colors of natural pigment emodin with superior stability through cocrystal engineering. *Cryst Growth Des* 2018;18:6123–32.

150. Sangtani E, Sahu SK, Thorat SH, Gawade RL, Jha KK, Munshi P, et al. Flexible molecular crystals based on a cocrystal approach. *Mater Horiz* 2020;7:142–57.

151. Bolla G, Nangia A. Pharmaceutical cocrystals: walking the talk. *Chem Comm* 2016;52:3342–60.
151. Childs SL, Kandi P, Lingreddie SR. Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability. *Mol Pharm* 2013;10:3112–27.

152. Huang Y, Zhang B, Gao Y, Zhang J, Shi L. Baicalein—nicotinamide cocrystal with enhanced solubility, dissolution, and oral bioavailability. *J Pharm Sci* 2014;103:2330–7.

153. Dai XL, Li S, Chen JM, Lu TB. Improving the membrane permeability of 5-fluorouracil via cocrystallization. *Cryst Growth Des* 2016;16:4430–8.

154. Zhi B, Zhang Q, Wang JR, Mei X. Cocrystals of baicaiccin with higher solubility and enhanced bioavailability. *Cryst Growth Des* 2017;17:1893–901.

155. Smith AJ, Kavuru P, Wojtas L, Zaworotko MJ, Shytle RD. Cocrystals of quercetin with improved solubility and oral bioavailability. *Mol Pharm* 2011;8:1867–76.

156. Martin F, Pop M, Kacso I, Grosu IJ, Baldea I. Ketoconazole-p-aminobenzoic acid cocrystal: revival of an old drug by crystal engineering. *Mol Pharm* 2019;17:919–32.

157. Ma XQ, Zhuang C, Wang BC, Huang YF, Chen Q, Lin N. Cocrystal of apigenin with higher solubility, enhanced oral bioavailability, and anti-inflammatory effect. *Cryst Growth Des* 2019;19:5531–7.

158. Alhake W, Jav M, Asad MMH, Hasan SMF, Hussain I. Improved in vitro and in vivo performance of carbamazepine enabled by using a succinic acid/cocrystal in a stable suspension formulation. *Pak J Pharm Sci* 2017;30:2139–45.

159. Alhalaweh A, Ali HRH, Velaga SP. Effects of polymer and surfactant on the dissolution and transformation profiles of cocrystals in aqueous media. *Cryst Growth Des* 2014;14:643–8.

160. Zadyevna OM, Poteshnov MA. Microemulsions and microheterogeneous microemulsion-based polymeric matrices for transdermal delivery of lipophilic drug (fetoldine). *Colloid Polym Sci* 2019;297:453–68.

161. Albus H, Neidhart B. Membrane-controlled reagent-delivery systems—a new approach for the continuous production of reagent and standard solutions. *Fresen J Anal Chem* 2001;370:893–8.

162. Ma L. Progress in osmotic pump drug delivery system. *J China Pharm Univ* 2014;45:726–30.

163. Yu XZ, Wang LY, Liu F, Li YT, Yan CW. A sustained-release dual drug ternary salt cocrystal of piperazine ferulate with pyrazinamide: the synthesis, structure and Hirshfeld surface analysis. *Cryst Growth Des* 2020;20:2064–73.

164. Aitipamula S, Cadden J, Chow PS. Cocrystals of zonamic acid: physicochemical characterization and sustained release solid forms. *CrystEngComm* 2018;20:2923–31.

165. Somphon W, Prasertsaw A, Jarusophon N. Novel cocrinding of donepezil with neurotransmitters and coumarins: characterization, physical properties and in vitro drug release study. *Mater Today* 2019;17:1887–97.

166. Chen J, Li S, Lu TB. Pharmaceutical cocrystals of ribavirin with reduced release rates. *Cryst Growth Des* 2014;14:6399–408.

167. Deng Y, Zhang Y, Huang Y, Zhang M, Lou B. Preparation, crystal structures, and oral bioavailability of two cocrystals of emodin with berberine chloride. *Cryst Growth Des* 2018;18:7481–8.

168. Zhou J, Li L, Zhang H, Xu J, Huang D, Gong N, et al. Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals. *Int J Pharm* 2020;576:118984.

169. Yuan Y, Li D, Wang C, Chen S, Zhang H. Structural features of sulfamethizole and its cocrystal: beauty within. *Cryst Growth Des* 2019;2019:7185–92.

170. Suresh K, Minkov VS, Namila KK, Derevyannikova E, Losev E, Nangia A, et al. Novel synthons in sulfamethizole cocrystals: structure—property relations and solubility. *Cryst Growth Des* 2015;15:3498–510.

171. Xuan B, Wong SN, Zhang Y, Weng J, Tong HHY, Wang C, et al. Extended release of highly water soluble isoniazid attained through cocrystallization with curcumin. *Cryst Growth Des* 2020;20:1951–60.

172. Maheshwari C, André V, Reddy S, Roy L, Duarte T, Rodriguez-Hornedo N. Tailoring aqueous solubility of a highly soluble compound via cocrystallization: effect of coformer ionization, pHMax and solute—solvent interactions. *CrystEngComm* 2012;14:4801–11.

173. Kumari N, Bhattacharya B, Roy P, Michalchuk AAL, Ghosh A. Enhancing the pharmaceutical properties of pirenidone by mechanochemical cocrystallization. *Cryst Growth Des* 2019;19:6842–92.

174. Gautam MK, Besan M, Pandit D, Mandal S, Chadha R. Cocrystal of 5-fluorouracil: characterization and evaluation of biopharmaceutical parameters. *AAPS PharmSciTech* 2019;20:149.

175. Wang LY, Bu FZ, Li YT, Wu ZY, Yan CW. A sulfathiazole—amantadine hydrochloride cocrystal: the first codrug simultaneously comprising antiviral and antibacterial components. *Cryst Growth Des* 2020;20:3236–46.

176. Liu F, Wang LY, Li YT, Wu ZY, Yan CW. Protective effects of quercetin against pyrazinamide induced hepatotoxicity via a cocrystallization strategy of Cocomplementary advantages. *Cryst Growth Des* 2018;18:3729–33.

177. Yu YM, Yu MC, Wang LY, Li YT, Wu ZY, Yan CW. A supramolecular adduct of tegafur and syringic acid: the first tegafur-nutracetical cocrystal with perfected in vitro and in vivo characteristics as well as synergized anticancer activities. *New J Chem* 2020;44:15994–6005.

178. Wang LL, Wang LY, Yu YM, Li YT, Wu ZY, Yan CW. Cocrystallization of 5-fluorouracil and l-phenylalanine: the first zwiterionic cocrystal of 5-fluorouracil with amino acid exhibiting perfect in vitro/vivo pharmaeutical properties. *CrystEngComm* 2020;22:5010–21.

179. Jubeen F, Liaquat A, Amjad F, Sultan M, Iqbal SZ, Sajjad I, et al. Synthesis of 5-fluorouracil cocrystals with novel organic acids as coformers and anticancer evaluation against HCT-116 colorectal cell lines. *Cryst Growth Des* 2020;20:2406–14.

180. Muresan-Pop M, Chereches G, Borodi G, Fischer-Fodor E, Simon S. Structural characterization of 5-fluorouracil & piperazine new solid forms and evaluation of their antitumor activity. *J Mol Struct* 2020;1207:127842.

181. Suresh Kumar S, Athimoolam S, Sridhar B. Structural, spectral, theoretical and anticancer studies on new co-crystal of the drug 5-fluorouracil. *J Mol Struct* 2018;1173:951–8.

182. Pan X, Zheng Y, Chen R, Qiu S, Chen Z, Rao W, et al. Co-crystal of sulfamethazine and p-aminobenzoic acid: structural establishment and enhanced antibacterial properties. *Cryst Growth Des* 2019;19:2455–60.

183. Liu F, Wang LY, Yu MC, Li YT, Wu ZY, Yan CW. A new cocrystal of isoniazid—quercetin with hepatoprotective effect: the design, structure, and in vitro/in vivo performance evaluation. *Eur J Pharm Sci* 2020;144:105216.

184. Chadha K, Karan M, Bhatta Y, Chadha R, Khullar S, Mandal S, et al. Cocrystals of hesperetin: structural, pharmacokinetic, and pharma-codynamic evaluation. *Cryst Growth Des* 2017;17:2386–405.

185. Vasishth K, Chadha K, Karan M, Bhatta Y, Jena AK, Chadha R. Enhancing biopharmaceutical parameters of bioflavonoid quercetin by cocrystallization. *CrystEngComm* 2016;18:1403–15.

186. Goyal P, Rani D, Chadha R. Crystal engineering: a remedy to tailor the biopharmaceutical aspects of glibenclamide. *Cryst Growth Des* 2017;18:105–18.

187. Saha R, Sengupta S, Dew SK, Steele IM, Bhattacharyya A, Biswas S, et al. A pharmaceutical cocrystal with potential anticancer activity. *RSC Adv* 2014;4:49070–8.
